LIST OF US PATENTS IN COSMETICS GRANTED IN  2012
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms
included formulations or compositions such as mascara, make-up, eye liner, lipstick, foundation, night creams, eye shadows, facial soap, nail polish, eye and lip care; formulation
ingredients such as pigments, opacifiers, colors, surfactants, polymers, cationic conditioning agents, formulation thickeners or rheology modifiers, dimethicones, vegetable-derived fatty
oils, petrolatum, mineral oils, emollients, sensory modifiers, perfumes and related aspects.
US Cosmetics Formulation Patents Granted in 2012
Clck to enlarge and view details
...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
US Patents Granted in 2013
US Patents Granted in 2011

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENTS IN COSMETIC FORMULATIONS GRANTED IN 2012



Patent No.: US8092789B1  Issued: 10/Jan/2012

Title: Indian meal moth attractant

Applicant/Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE

Application No.: 12/362236   Filing Date: 29/Jan/2009

Abstract:

A composition containing undecane, hexanal, 1-pentanol, decane, and 2-pentylfuran is an effective attractant for adult female Indian meal moths (Plodia interpunctella). The composition may be used alone or with a carrier component. The composition may be used in combination with any insect trapping means known in the art, as required for a specific application.

Priority:

Inventor: TEAL PETER E A [US]; SILHACEK DON L [US]


Patent No.: US8092815B2  Issued: 10/Jan/2012

Title: ANTIMICROBIAL SOLID SURFACE MATERIALS CONTAINING CHITOSAN-METAL COMPLEXES

Applicant/Assignee: E. L. DUPONT DE NEMOURS AND COMPANY, E. I. DU PONT DE NEMOURS AND COMPANY

Application No.: 12/107253   Filing Date: 22/Apr/2008

Abstract:

Provided are articles containing a solid surface material with an antimicrobial agent in a thermoset and/or thermoplastic resin matrix, wherein the antimicrobial agent comprises a chitosan-metal complex.

Priority: US2001-343321P Applic. Date: 2001-12-21; US2004-999672 Applic. Date: 2004-11-30; US2002-324803 Applic. Date: 2002-12-20

Inventor: SABESAN SUBRAMANIAM [US]


Patent No.: US8092827B2  Issued: 10/Jan/2012

Title: Medical non-crosslinked pressure-sensitive adhesive composition, medical adhesive sheet employing the same, and process for producing medical non-crosslinked pressure-sensitive adhesive composition

Applicant/Assignee: NITTO DENKO CORPORATION

Application No.: 11/113969   Filing Date: 26/Apr/2005

Abstract:

A medical non-crosslinked pressure-sensitive adhesive composition which not only has relatively high resistance to water during perspiration or the like and shows a sufficient skin adhesive force, but also can contain a large amount of a liquid plasticizer and hence have reduced skin-irritating properties.

These compositions comprise an adhesive polymer A having a weight-average molecular weight of 500,000-1,000,000, an adhesive polymer B having a weight-average molecular weight of 1,000,000-1,500,000, and a liquid plasticizer, wherein the adhesive polymer A is a polymer obtained by copolymerizing one or more alkyl (meth)acrylates with N-vinyl-2-pyrrolidone and the adhesive polymer B is either a polymer obtained by the polymerization of one or more alkyl (meth)acrylates or a polymer obtained by copolymerizing one or more alkyl (meth)acrylates with one or more comonomers other than N-vinyl-2-pyrrolidone. Also provided are a medical adhesive sheet and a process for producing the medical non-crosslinked pressure-sensitive adhesive composition.

Priority: JP20040131809 Applic. Date: 2004-04-27

Inventor: INOSAKA KEIGO [JP]; MURAOKA TAKATERU [JP]


Patent No.: US8093203B2  Issued: 10/Jan/2012

Title: Method of enhancing fragrance by adding optically active muscone composition

Applicant/Assignee: TAKASAGO INTERNATIONAL CORPORATION

Application No.: 11/719109   Filing Date: 12/Nov/2004

Abstract:

The object of the invention relates to a development of a new musk-feeling fragrance material which is a highly scenting musk-feeling fragrance, and is to provide a fragrance composition which, when added to fragrances or cosmetics, can improve the fixative property and express a high performance and excellent musky aromatic quality. A fragrance composition is prepared using, as the active ingredient, a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 90:10 to 95:5 (weight ratio) in terms of weight ratio, or a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 75:25 to 80:20 (weight ratio) in terms of weight ratio.

Priority: WO2004JP16825 Applic. Date: 2004-11-12

Inventor: YAMAMOTO KENICHI [JP]; YAGI MISAO [JP]; MATSUDA HIROYUKI [JP]; MARUYAMA KENJI [JP]


Patent No.: US8101114B2  Issued: 24/Jan/2012

Title: Particle Based Molding

Applicant/Assignee: GEORGIA TECH RESEARCH CORPORATION

Application No.: 12/299092   Filing Date: 30/Apr/2007

Abstract:

Various apparatuses, arrangements, and methods are provided for creating various structures including microstructures. In one embodiment, a method for creating a microstructure is provided comprising packing a plurality of particles into a micromold, and then applying energy to the particles in the micromold. As a result of the application of energy, a microstructure is formed in the micromold out of the particles. Thereafter, the microstructure is removed from the micromold.

Priority: US2006-796419P Applic. Date: 2006-05-01; WO2007US67776 Applic. Date: 2007-04-30

Inventor: PARK JUNG-HWAN [US]; ALLEN MARK G [US]; PRAUSNITZ MARK R [US]


Patent No.: US8101206B2  Issued: 24/Jan/2012

Title: Method of attenuating swelling or inflammation

Applicant/Assignee: FERRIS PHARMACEUTICALS, INC, SESSIONS PHARMACEUTICALS INC

Application No.: 11/541082   Filing Date: 29/Sep/2006

Abstract:

The present invention provides a method of attenuating the formation or reducing the severity of swelling and/or inflammation in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of swelling and/or inflammation.

Priority: US2006-440550 Applic. Date: 2006-05-25; US2002-175119 Applic. Date: 2002-06-19; US2001-789275 Applic. Date: 2001-02-20; US1999-326836 Applic. Date: 1999-06-07; US1998-088424P Applic. Date: 1998-06-08

Inventor: SESSIONS ROBERT W [US]; KAHN ALAN R [US]


Patent No.: US8101630B2  Issued: 24/Jan/2012

Title: Extended release opioid abuse deterrent compositions and methods of making same

Applicant/Assignee: ACURA PHARMACEUTICALS, INC

Application No.: 12/383906   Filing Date: 30/Mar/2009

Abstract:

This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.

Priority: US2003-723654 Applic. Date: 2003-11-26; US2007-716122 Applic. Date: 2007-03-09

Inventor: KUMAR VIJAI [US]; DIXON DAVID [US]; TEWARI DIVYA [US]; WADGAONKAR DILIP B [US]


Patent No.: US8105617B2  Issued: 31/Jan/2012

Title: CATIONIC COPOLYMERS FORMULATED WITH PIGMENTED COSMETIC COMPOSITIONS EXHIBITING RADIANCE WITH SOFT FOCUS

Applicant/Assignee: CONOPCO, INC., D/B/A UNILEVER, CONOPCO, INC

Application No.: 12/335553   Filing Date: 16/Dec/2008

Abstract:

A cosmetic composition is provided which includes a silicone elastomer, a cationic copolymer with monomeric units selected from at least an acryloylethyl tri(C1-C3 alkyl)ammonium salt, and light reflecting platelet shaped particles. The compositions are particularly useful to impart radiance as well as soft focus effects onto the skin. A particular useful cationic copolymer is that of acrylamide/acryloylethyl trimethylammonium chloride/tris(hydroxymethyl)acrylamidomethane copolymer.

Priority: US2008-029654P Applic. Date: 2008-02-19

Inventor: POLONKA JACK [US]; BARTOLONE JOHN BRIAN [US]


Patent No.: US8105618B2  Issued: 31/Jan/2012

Title: Method for treatment of common acne

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: 12/884684   Filing Date: 17/Sep/2010

Abstract:

Dermatological/cosmetic gel compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise (i) at least one retinoid, (ii) dispersed benzoyl peroxide and (iii) at least one pH-independent gelling agent, formulated into (iv) a physiologically acceptable medium therefor.

Priority: FR20010016747 Applic. Date: 2001-12-21; US2002-351382P Applic. Date: 2002-01-28; US2002-326389 Applic. Date: 2002-12-23

Inventor: ORSONI-SEGURA SANDRINE [FR]; WILLCOX NATHALIE [FR]


Patent No.: US8105628B2  Issued: 31/Jan/2012

Title: Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects

Applicant/Assignee: ORTHOCON, INC

Application No.: 10/941890   Filing Date: 16/Sep/2004

Abstract:

Two (or more), -component, body-implantable, absorbable, biocompatible, putty, and non-putty hemostatic tamponades for use in surgery. Component 1 is a finely powdered bulking material, preferably less than 50 microns, e.g. the calcium, magnesium, aluminum, or barium salts of saturated or unsaturated carboxylic acids containing about 6 to 22 carbon atoms, hydroxyapatite, DBM, polyglycolide, polylactide, polydioxinones, polycaprolactones, absorbable glasses, gelatin, collagens, mono, and polysaccharides starches. Component 2, a dispersing vehicle, may be esters of C8-C18 monohydric alcohols with C2-C6 aliphatic monocarboxylic acids

C2-C18 monohydric alcohols with polycarboxylic acids

C8-C30 monohydric alcohols

tocopherol and esters thereof with C2-C10 aliphatic monocarboxylic acids or polycarboxylic acids

absorbable 10-14C hydrocarbons

free carboxylic acids such as oleic, capric, and lauric

dialkyl ethers and ketones

alkyl aryl ethers and ketones, polyhydroxy compounds and esters and ethers thereof

(ethylene oxide/propylene oxide copolymers), oils e.g. olive oil, castor oil and triglycerides.

Priority: US2003-504978P Applic. Date: 2003-09-23

Inventor: KRONENTHAL RICHARD L [US]


Patent No.: US8105652B2  Issued: 31/Jan/2012

Title: Methods of Making Decomposable Thin Films of Polyelectrolytes and Uses Thereof

Applicant/Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Application No.: 11/459979   Filing Date: 26/Jul/2006

Abstract:

A decomposable thin film comprising a plurality of polyelectrolyte layers of alternating charge, wherein decomposition of the thin film is characterized by degradation of at least a portion of the polyelectrolyte layers.

Priority: US2002-280268 Applic. Date: 2002-10-24; US2006-809640P Applic. Date: 2006-05-30

Inventor: WOOD KRIS C [US]; CHUANG HELEN F [US]; BATTEN ROBERT D [US]; LYNN DAVID M [US]; HAMMOND CUNNINGHAM PAULA T [US]


Patent No.: US8106146B2  Issued: 31/Jan/2012

Title: THERAPEUTIC POLYMERS AND METHODS OF GENERATION

Applicant/Assignee: MEDTRONIC, INC

Application No.: 12/766676   Filing Date: 23/Apr/2010

Abstract:

The invention describes poly(ortho ester) polymers that include at least one therapeutic compound in the polymer backbone. The therapeutic compound includes at least one phenol residue and an aliphatic alcohol residue or two or more phenolic residues.

Priority: US2009-249098P Applic. Date: 2009-10-06

Inventor: BENZ MICHAEL E [US]; TENBROEK ERICA M [US]; LUO LIAN LEON [US]


Patent No.: US8114428B2  Issued: 14/Feb/2012

Title: Methods for manufacturing a composition for treating bone and/or cartilage defects

Applicant/Assignee: SBF SYNTHETIC BONE FACTORY GMBH

Application No.: 12/554940   Filing Date: 07/Sep/2009

Abstract:

The present invention relates to compositions devices and methods for treating bone and/or cartilage defects, and a method for manufacturing such a composition or device. In a certain embodiment, the invention provides a device and/or composition for treating bone and/or cartilage defects, having at least one collagen, for example of animal origin, and further containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect, and at least one filling material, in which the composition is in the form of a lyophil.

Priority: DE200710012276 Applic. Date: 2007-03-08; US2007-993146P Applic. Date: 2007-09-10; WO2008IB02367 Applic. Date: 2008-09-05

Inventor: BRIEST ARNE [DE]


Patent No.: US8114670B2  Issued: 14/Feb/2012

Title: Skin Equivalent Culture

Applicant/Assignee: DFB TECHNOLOGY HOLDINGS, LLC

Application No.: 11/886113   Filing Date: 14/Mar/2006

Abstract:

Methods of forming soft connective tissue compositions such as skin equivalents, compositions made by the methods and their uses. In particular, a method of forming a connective tissue equivalent, comprising the steps of: (i) incubating collagen-producing cells in or on a support matrix

(ii) inducing and/or enhancing collagen production by the collagen-producing cells to form a collagenous construct and degradation and replacement of the support matrix

(iii) freeze-drying the construct

and (iv) re-populating the freeze-dried construct with collagen-producing cells and/or epithelial cells and/or endothelial cells and/or mesenchymal cells, thereby forming a connective tissue equivalent, wherein: (a) the collagen-producing cells are substantially fibroblasts

for example human neonatal dermal fibroblasts

(b) the support matrix is a provisional support matrix in which the support matrix is a fibrin matrix, for example formed by thrombin-mediated polymerisation of fibrinogen

and (c) as a result of the collagen production by the collagen-producing cells the provisional fibrin support matrix is digested by the cells and is replaced by collagen, thereby essentially replacing the provisional fibrin matrix with a collagen matrix synthesised in situ by the cells.

Priority: GB20050005202 Applic. Date: 2005-03-14; WO2006GB00890 Applic. Date: 2006-03-14

Inventor: KEMP PAUL [GB]; SHERING DAVID [GB]; JOHNSON PENNY [GB]; MARSHALL DAMIAN [GB]


Patent No.: US8114841B2  Issued: 14/Feb/2012

Title: Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix

Applicant/Assignee: BIOMIMETIC THERAPEUTICS, INC

Application No.: 11/601376   Filing Date: 17/Nov/2006

Abstract:

The present invention provides effective new methods and materials for maxillofacial bone augmentation, particularly alveolar ridge augmentation, that are free of problems associated with prior art methods. In one embodiment, these materials include human recombinant platelet derived growth factor (rhPDGF-BB) and a biocompatible matrix. In another embodiment, these materials include rhPDGF-BB, a deproteinized bone block or calcium phosphate, and a bioresorbable membrane. The use of these materials in the present method is effective in regenerating maxillofacial bones and facilitating achievement of stable osseointegrated implants. The mandible and maxilla are preferred bones for augmentation, and enhancement of the alveolar ridge is a preferred embodiment of the present invention.

Priority: US2005-159533 Applic. Date: 2005-06-23; US2004-965319 Applic. Date: 2004-10-14; US2005-738076P Applic. Date: 2005-11-17

Inventor: LYNCH SAMUEL E [US]; NEVINS MYRON [US]; SIMION MASSIMO [IT]


Patent No.: US8119168B2  Issued: 21/Feb/2012

Title: Personal care compositions comprising a zinc containing material in an aqueous surfactant composition

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: 10/392422   Filing Date: 18/Mar/2003

Abstract:

Disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25 DEG C.

from about 5% to about 50% of a surfactant

and from about 40% to about 95% water

wherein the pH of the composition is greater than about 7. Further disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25 DEG C.

from about 5% to about 50% of a surfactant

and from about 0.1% to about 5% of a zinc ionophoric material

from about 40% to about 95% water

and wherein the pH of the composition is greater than about 7.

Priority: US2002-374346P Applic. Date: 2002-04-22

Inventor: JOHNSON ERIC SCOTT [US]; CRANE ELIZABETH ANN [US]; SCHWARTZ JAMES ROBERT [US]; MARGRAF III CARL HINZ [US]; TORMOS GREGORY V [US]; WARNKE DAVID THOMAS [US]


Patent No.: US8124127B2  Issued: 28/Feb/2012

Title: Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings

Applicant/Assignee: ATRIUM MEDICAL CORPORATION

Application No.: 11/582135   Filing Date: 16/Oct/2006

Abstract:

Coatings for medical devices, methods of making the coatings, and methods of using them are described.

Priority: US2005-727312P Applic. Date: 2005-10-15

Inventor: FAUCHER KEITH M [US]; TANG HUI [US]; ROGERS LISA [US]; FERRARO JOSEPH [US]; MARTAKOS PAUL [US]; HERWECK STEVE A [US]; KARWOSKI THEODORE [US]


Patent No.: US8133508B2  Issued: 13/Mar/2012

Title: Fluorescent cosmetic composition

Applicant/Assignee: L'OREAL

Application No.: 11/540651   Filing Date: 02/Oct/2006

Abstract:

The present invention relates to a cosmetic composition containing, in a physiologically acceptable medium, fluorescent particles comprising molecules of at least one fluorescent organic compound trapped inside a matrix at least partially formed by at least one metal oxide, said composition comprising less than 100 mg/l of said fluorescent organic compound or compounds dissolved in a liquid phase of the medium.

Priority: US2005-722448P Applic. Date: 2005-10-03

Inventor: DUMOUSSEAUX CHRISTOPHE [JP]


Patent No.: US8133924B2  Issued: 13/Mar/2012

Title: Demulsifiers and methods for use in pharmaceutical applications

Applicant/Assignee: RHODIA INC, RHODIA OPERATIONS

Application No.: 12/384262   Filing Date: 02/Apr/2009

Abstract:

Demulsifiers containing an anionic surfactant selected from alkylsulfosuccinates, alkylsulfonates, alkylphosphonic acids, and their salts

a nonionic surfactant selected from ethylene oxide/propylene oxide copolymers, ethoxylated fatty acids of polyethylene glycol, terpene alkoxylates, and modified alkanolamides

or a combination of an anionic and a nonionic surfactant, and methods of use thereof in breaking emulsions.

Priority: US2008-072768P Applic. Date: 2008-04-02; US2007-955551P Applic. Date: 2007-08-13; US2008-191130 Applic. Date: 2008-08-13

Inventor: TALINGTING-PABALAN RUELA [US]; DAHANAYAKE MANILAL S [US]; WOODWARD GARY [GB]; ADAM HERVE [US]


Patent No.: US8137689B1  Issued: 20/Mar/2012

Title: Transplant/implant device and method for its production

Applicant/Assignee: ZIMMER GMBH

Application No.: 10/129915   Filing Date: 13/Nov/2000

Abstract:

A transplant/implant device for delivering at least one predetermined biologically active compound to a human or animal host system or for another biological function in the host system is produced by genetically engineering vital chondrocytes or mixing chondrocytes with another type of native or genetically engineered cells or mixing chondrocytes with artificial particles having a size comparable to the size of cells or combining at least two of the named steps of engineering or mixing and by subjecting the chondrocytes or the mixture comprising the chondrocytes to three dimensional culture conditions for in vitro production of cartilaginous tissue whereby the cells and/or the artificial particles are immobilized in the cartilaginous tissue. The chondrocytes produce and maintain the cartilaginous tissue and the chondrocytes themselves or cells of another cell type immobilized in the cartilaginous tissue are able to produce and secrete the at least one predetermined compound.

Priority: EP19990122460 Applic. Date: 1999-11-11; WO2000CH00602 Applic. Date: 2000-11-13

Inventor: GROGAN SHAWN P [AU]; MAINIL-VARLET PIERRE [CH]; MUELLER WERNER [CH]; SCHAFFNER THOMAS [CH]


Patent No.: US8137696B2  Issued: 20/Mar/2012

Title: BIOMIMETIC COMPOSITION REINFORCED BY A POLYELECTROLYTIC COMPLEX OF HYALURONIC ACID AND CHITOSAN

Applicant/Assignee: TISSUE ENGINEERING CONSULTANTS, INC

Application No.: 12/410537   Filing Date: 25/Mar/2009

Abstract:

The present invention relates to a three dimensional, malleable cell culture composition and method of forming the same comprising hyaluronic acid, chitosan and a polyelectrolytic complex of hyaluronic acid and chitosan. These three components in combination constitute an initial microenvironment for support of stromal cells, and their undifferentiated mesenchymal cell progeny. The tissue engineering device and method of forming the same comprising hyaluronic acid and chitosan and the use of said device with compositions of pluripotent cells and various formulations of cell culture media for repair of tissues is disclosed.

Priority: US2004-999848 Applic. Date: 2004-11-30; US2003-525965P Applic. Date: 2003-12-01

Inventor: BREKKE JOHN H [US]


Patent No.: US8137703B2  Issued: 20/Mar/2012

Title: Ozone Water And Production Method Therefor

Applicant/Assignee: REO LABORATORY CO., LTD, NATIONAL INSTITUTE OF AIST

Application No.: 10/591978   Filing Date: 28/Feb/2005

Abstract:

The present invention relates to an ozone water that has the potential to find useful applications in a wide variety of technical fields and is capable of maintaining the effects of wiping out microorganisms such as bacteria, viruses and the like and inhibiting the growth thereof over long periods. The present invention provides ozone nano-bubbles capable of staying in a solution for an extended period of time and a method for producing the ozone nano-bubbles by instantaneously shrinking the diameters of ozone microbubbles contained in an aqueous solution by the application of a physical irritation to the ozone microbubbles in an aqueous solution.

Priority: JP20040062156 Applic. Date: 2004-03-05; WO2005JP03811 Applic. Date: 2005-02-28

Inventor: CHIBA KANEO [JP]; TAKAHASHI MASAYOSHI [JP]


Patent No.: US8137734B2  Issued: 20/Mar/2012

Title: PREPARATION OF CONTROLLED RELEASE SKELETAL MUSCLE RELAXANT DOSAGE FORMS

Applicant/Assignee: APTALIS PHARMATECH, INC

Application No.: 12/487339   Filing Date: 18/Jun/2009

Abstract:

The present invention is directed to a method of preparing an extended release pharmaceutical composition comprising cyclobenzaprine, comprising coating inert particles with a cyclobenzaprine-containing a drug layering composition to form IR beads, then coating the IR beads with an extended-release coating to form ER beads.

Priority: US2008-074464P Applic. Date: 2008-06-20

Inventor: VENKATESH GOPI M [US]; CLEVENGER JAMES M [US]; GRINSTEAD TIMOTHY [US]


Patent No.: US8142562B2  Issued: 27/Mar/2012

Title: CURABLE DENTAL RETRACTION COMPOSITION, METHOD OF PRODUCTION AND USE THEREOF

Applicant/Assignee: 3M INNOVATIVE PROPERTIES COMPANY

Application No.: 12/376527   Filing Date: 02/Aug/2007

Abstract:

The invention relates to a curable dental retraction composition for reacting gingiva from a prepared tooth structure. The composition comprises an alginate, a di- and/or trivalent ion source, water, a retarder and a filler.

Priority: EP20060016477 Applic. Date: 2006-08-08; WO2007US75065 Applic. Date: 2007-08-02

Inventor: KLETTKE THOMAS [DE]; HAMPE RUEDIGER [DE]


Patent No.: US8142764B2  Issued: 27/Mar/2012

Title: Synthetic biofilm-inhibiting peptides

Applicant/Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION

Application No.: 12/392966   Filing Date: 25/Feb/2009

Abstract:

The present invention provides streptococcal SspB Adherence Region (BAR) peptides consisting of Formula I: R18-R1- R2-Val-R3-R4-Leu-Leu-R5-R6-R7-Ile-R8-R9-Lys-R10-R19 , wherein R2, is 1-3 Lys residues

R3 is any amino acid residue except a Pro residue

R4 is any amino acid residue except a Pro residue

R5 is 1-3 Lys residues

R6 is 1-10 amino acid residues

R7 is any amino acid residue except Asp, Glu, Gly or Pro

R8 is any amino acid residue except Ala, Asp, Gly, His, Ile, Pro, Trp or Tyr

R9 is a Val, Ile, Phe, or Trp residue

R10 is 0-1 Cys residue

R18 is 0 amino acids or R12-R11-Pro-, wherein R11 is 0-3 amino acids, wherein the amino acid residues are not Gly or Pro

and R12 is 0-1 Cys residues

and R19 is R13-R14-R15-R16-R17, wherein R13 is 0-1 is Gly residue

R14 is 0-1 Ala residue

R15 is 0-1 Phe residue

R16 is 0-1 Gln residue

R17 is 0-1 Cys residue

and wherein R1 is an ornithine residue

or wherein both R1 and R10 are both Cys and R1 and R10 are covalently linked to form a circular peptide

or wherein R1 is 0-1 Cys or an ornithine residue and R12 and R17, are both Cys and R12 and R17 are covalently linked to form a circular peptide. Embodiments of the present invention further provide devices coated with the BAR peptides.

Priority: US2008-031934P Applic. Date: 2008-02-27; US2008-127797P Applic. Date: 2008-05-14

Inventor: DEMUTH DONALD R [US]; DAEP CARLO AMORIN [US]


Patent No.: US8142811B2  Issued: 27/Mar/2012

Title: Controlled release hydrocodone formulations

Applicant/Assignee: PURDUE PHARMA LP, PURDUE PHARMA L.P

Application No.: 12/378586   Filing Date: 17/Feb/2009

Abstract:

A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

Priority: US2003-660349 Applic. Date: 2003-09-11; US2001-016651 Applic. Date: 2001-10-30; US2000-244424P Applic. Date: 2000-10-30

Inventor: OSHLACK BENJAMIN [US]; HUANG HUA-PIN [US]; MASSELINK JOHN K [US]; TONELLI ALFRED P [US]


Patent No.: US8142812B2  Issued: 27/Mar/2012

Title: Chemical carrier based on a beta-limit dextrin

Applicant/Assignee: GLYCOLOGIC LIMITED

Application No.: 10/517558   Filing Date: 13/Jul/2005

Abstract:

A formulation, especially a pharmaceutical formulation, comprises an active agent and a carrier for the active agent, wherein the carrier comprises a beta-limit dextrin. The formulation may be a bioadhesive pharmaceutical formulation in which the beta-limit dextrin acts as a mucoadhesive agent. The active agent is a pharmaceutically active agent or a flavour or fragrance which is intended for delivery into the buccal cavity. A use of beta-limit dextrin as a disintegrant, a dispersant, and a mucoadhesive agent is also described. Also described is a nutritional product such as an energy drink which includes beta-limit dextrin as an energy source.

Priority: WO2003EP08358 Applic. Date: 2003-07-29; GB20020017930 Applic. Date: 2002-08-02

Inventor: TESTER RICHARD FRANK [GB]; QI XIN [GB]


Patent No.: US8147866B2  Issued: 03/Apr/2012

Title: TRANSMUCOSAL DELIVERY DEVICES WITH ENHANCED UPTAKE

Applicant/Assignee: BIODELIVERY SCIENCES INTERNATIONAL, INC

Application No.: 13/184306   Filing Date: 15/Jul/2011

Abstract:

The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.

Priority: US2007-817915 Applic. Date: 2007-07-23; WO2007US16634 Applic. Date: 2007-07-23; US2006-832725P Applic. Date: 2006-07-21; US2006-832726P Applic. Date: 2006-07-21; US2006-839504P Applic. Date: 2006-08-23

Inventor: FINN ANDREW [US]; VASISHT NIRAJ [US]


Patent No.: US8153696B2  Issued: 10/Apr/2012

Title: Medicinal preparation particularly for the treatment of slipped discs hernias

Applicant/Assignee:

Application No.: 12/870258   Filing Date: 27/Aug/2010

Abstract:

The invention concerns a product consisting in an injection medicinal formulations comprising at least one compound to provide a viscous formulation, ethanol and at least one compound making said formulation opaque to X rays so as to control its delivery and its action. Said formulation is in particular useful for treating herniated invertebral discs but also in intervention having demonstrated the efficacy of pure ethanol: treatment of hepatocellular tumours or osteoid osteomas, renal cysts and arterial-veinous angiomas.

Priority: FR20020005819 Applic. Date: 2002-05-07; US2005-513592 Applic. Date: 2005-11-30; WO2003FR01412 Applic. Date: 2003-05-07

Inventor: THERON JACQUES [FR]; D ABOVILLE MARC [FR]


Patent No.: US8168163B2  Issued: 01/May/2012

Title: [(4E, 4Z)-5-METHOXY-3-METHYL-4-PENTENYL]-BENZENE AND ITS USE IN PERFUME COMPOSITIONS

Applicant/Assignee: INTERNATIONAL FLAVORS & FRAGRANCES, INC

Application No.: 12/637827   Filing Date: 15/Dec/2009

Abstract:

The present invention is directed to a novel compound, [(4E,4Z)-5-methoxy-3-methyl-4-pentenyl]-benzene, and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of this novel compound.

Priority:

Inventor: NARULA ANUBHAV P S [US]; ARRUDA EDWARD MARK [US]


Patent No.: US8168215B2  Issued: 01/May/2012

Title: ALGINATE COATED, COLLAGEN MATRIX CELLULAR DEVICE, PREPARATIVE METHODS, AND USES THEREOF

Applicant/Assignee: FMC BIOPOLYMER AS

Application No.: 11/762680   Filing Date: 13/Jun/2007

Abstract:

The present invention is directed to cellular devices comprising a collagen matrix, cell layer, and gelled alginate layer, processes for producing the devices, methods of implanting the devices, and methods of treatment thereof.

Priority: US2006-814404P Applic. Date: 2006-06-16

Inventor: DUFRANE DENIS [BE]; GIANELLO PIERRE RENE RAYMOND [BE]; MELVIK JAN EGIL [NO]


Patent No.: US8168619B1  Issued: 01/May/2012

Title: Hormonal composition based on a progestational agent and an oestrogen and use thereof

Applicant/Assignee: LABORATOIRE THERAMEX

Application No.: 09/423109   Filing Date: 29/Oct/1999

Abstract:

A method of preventing estrogen deficiencies and osteoporosis in menopausal women by continuously orally administering without interruption to menopausal women in need thereof an amount of 0.3 to 3 mg of 17[beta]-estradiol or esters thereof and 0.3 to 1.25 mg of nomegestrol or esters thereof in an amount sufficient to prevent said problems.

Priority: WO1999FR02588 Applic. Date: 1999-10-25

Inventor: PARIS JACQUES [FR]; THOMAS JEAN-LOUIS [FR]


Patent No.: US8168629B2  Issued: 01/May/2012

Title: Analgesic combination of tramadol and meloxicam

Applicant/Assignee: PURDUE PHARMA L.P

Application No.: 11/825938   Filing Date: 10/Jul/2007

Abstract:

Disclosed is a pharmaceutical composition, comprising a combination of a dose of meloxicam or a pharmaceutically acceptable salt thereof and a dose of tramadol or a pharmaceutically acceptable salt thereof, the combination in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising administering to the patient a combination of a dose of meloxicam or a pharmaceutically acceptable salt thereof and a dose of tramadol or a pharmaceutically acceptable salt thereof such that the dosing interval of the meloxicam overlaps with the dosing interval of the tramadol, the combination in an amount sufficient to provide an analgesic effect in a human patient.

Priority: US1997-059195P Applic. Date: 1997-09-17; US1998-154354 Applic. Date: 1998-09-17; US2002-056347 Applic. Date: 2002-01-25

Inventor: BURCH RONALD M [US]; GOLDENHEIM PAUL D [US]; SACKLER RICHARD S [US]


Patent No.: US8172861B2  Issued: 08/May/2012

Title: COMPOSITIONS AND METHODS FOR JOINING NON-CONJOINED LUMENS

Applicant/Assignee: SYNVASCULAR, INC, TAUTONA GROUP, L.P

Application No.: 12/340586   Filing Date: 19/Dec/2008

Abstract:

Sol-gel compositions, methods, and kits for joining together non-conjoined lumens in a patient's body including vascular lumens. More particularly, in various aspects, this invention provides thermoreversible sol-gel compositions, methods, and kits for joining such non-conjoined lumens, including small lumens typically requiring microsurgical technique.

Priority: US2007-015660P Applic. Date: 2007-12-20

Inventor: FULLER GERALD G [US]; RAPPLEYE C TRAVIS [US]; MANDRUSOV EVGENIA [US]


Patent No.: US8173150B2  Issued: 08/May/2012

Title: STABLE NON-AQUEOUS SINGLE PHASE VISCOUS VEHICLES AND FORMULATIONS UTLIZING SUCH VEHICLES

Applicant/Assignee: INTARCIA THERAPEUTICS, INC

Application No.: 13/043288   Filing Date: 08/Mar/2011

Abstract:

This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 110-7 reciprocal second.

Priority: US2008-075435 Applic. Date: 2008-03-11; US1999-119170P Applic. Date: 1999-02-08; US2000-497422 Applic. Date: 2000-02-03; US2000-627531 Applic. Date: 2000-07-28

Inventor: BERRY STEPHEN A [US]; FEREIRA PAMELA J [US]; DEHNAD HOUDIN [US]; MUCHNIK ANNA [US]


Patent No.: US8173155B2  Issued: 08/May/2012

Title: Adhesive patch

Applicant/Assignee: HISAMITSU PHARMACEUTICAL CO., INC

Application No.: 11/141727   Filing Date: 31/May/2005

Abstract:

The present invention relates an adhesive patch comprising a backing layer and an adhesive layer that contains a drug, wherein the adhesive layer contains a mixed adhesive base containing a hydrocarbon rubber and a silicon-containing polymer. The adhesive patch of the invention shows extremely superior skin absorbability of a drug in a preparation, reduced skin irritation, and excellent aging stability of the drug in the preparation, and can achieve easiness of drug-taking methods and improvement in compliance.

Priority: JP20040163286 Applic. Date: 2004-06-01

Inventor: YASUKOCHI TAKASHI [JP]; TATEISHI TETSURO [JP]; HIGO NARUHITO [JP]


Patent No.: US8173162B2  Issued: 08/May/2012

Title: Preparation for repairing cartilage tissue, especially articular cartilage defects

Applicant/Assignee: ZIMMER ORTHOBIOLOGICS, INC

Application No.: 10/547437   Filing Date: 23/Feb/2004

Abstract:

The invention relates to preparations which are suitable for repairing enchondral or osteochondral defects (4) by means of implantation, said preparations comprising a cartilage element (A) and optionally a bone element (B) which is connected to the cartilage element (A). The cartilage element (A) can already contain cells during the implantation or is populated after the implantation with cells migrating from surrounding tissue. The aim of the invention is to better equip the cartilage element (A) of one such preparation for integration into the surrounding tissue and/or for an easy-to-achieve, primary stability. To this end, said cartilage element is not homogeneously embodied but has different characteristics in a peripheral and/or basal region (2, 3) to those in a central region (3).

Said differing characteristics (A) relate to the structure and/or composition of the matrix used and/or to the cells established in the matrix, and are in no way used to prevent the migration of cells into the preparation from the surrounding tissue.

Priority: WO2004CH00093 Applic. Date: 2004-02-23; CH20030000296 Applic. Date: 2003-02-26

Inventor: VILEI SIMONA BERARDI [CH]; BITTMANN PETER [CH]; WAGNER PHILIPP [CH]; FRENZ MARTIN [CH]


Patent No.: US8173637B2  Issued: 08/May/2012

Title: Stabilized Atypical Antipsychotic Formulation

Applicant/Assignee: HANDA PHARMACEUTICALS, LLC

Application No.: 12/205356   Filing Date: 05/Sep/2008

Abstract:

A pharmaceutical composition that contains an atypical antipsychotic drug and succinic acid, fumaric acid or a mixture of succinic acid and fumaric acid.

Priority: US2008-083270P Applic. Date: 2008-07-24

Inventor: LIU FANG-YU [US]; SHEN ZHI-QUN [CN]


Patent No.: US8178099B2  Issued: 15/May/2012

Title: METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONIST

Applicant/Assignee: OSTEOGENEX INC

Application No.: 11/962522   Filing Date: 21/Dec/2007

Abstract:

The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.

Priority: US2006-882642P Applic. Date: 2006-12-29

Inventor: ELLIES DEBRA L [US]


Patent No.: US8188065B2  Issued: 29/May/2012

Title: BOLDINE COMPOUNDS FOR PROMOTING BONE GROWTH

Applicant/Assignee: OSTEOGENEX INC

Application No.: 12/571623   Filing Date: 01/Oct/2009

Abstract:

The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer.

Priority: US2008-102084P Applic. Date: 2008-10-02

Inventor: ELLIES DEBRA [US]; ROSENBERG WILLIAM [US]


Patent No.: US8188204B2  Issued: 29/May/2012

Title: POLYMERS, COMPOSITIONS AND METHODS FOR USE FOR FOAMS, LAUNDRY DETERGENTS, SHOWER RINSES AND COAGULANTS

Applicant/Assignee: RHODIA INC

Application No.: 13/070655   Filing Date: 24/Mar/2011

Abstract:

The present invention relates to a polymeric material comprising units capable of having a cationic charge at a pH of from about 4 to about 12

provided that said polymeric material has an average cationic charge density from about 2.75 or less units per 100 daltons molecular weight at a pH of from about 4 to about 12. The polymeric material is a suds enhancer and a suds volume extender for hand dishwashing compositions and personal care products such as soaps, shaving cream foam, foaming shaving gel, foam dephiliatories and shampoos. The polymers are also effective as a soil release agent in fabric cleaning compositions. The polymers are also useful in agrochemical foam, fire-fighting foam, hard surface cleaner foam, and coagulant for titanium dioxide in paper making.

Priority: WO2000US14456 Applic. Date: 2000-05-25; US2000-698479 Applic. Date: 2000-10-30; US1999-318941 Applic. Date: 1999-05-26

Inventor: BERGERON VANCE [FR]; YEUNG DOMINIC WAI-KWING [CA]; BODET JEAN-FRANCOIS [US]; SIVIK MARK ROBERT [US]; KLUESENER BERNARD WILLIAM [US]; SCHEPER WILLIAM MICHAEL [US]


Patent No.: US8192485B2  Issued: 05/Jun/2012

Title: Reversible hydrogel systems and methods therefor

Applicant/Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF VETERENS AFFAIRS, THE WASHINGTON UNIVERSITY IN ST. LOUIS

Application No.: 10/706081   Filing Date: 13/Nov/2003

Abstract:

The present invention relates to reversible hydrogel systems for medical applications. Particularly, the hydrogel of the present invention is made up of copolymers that can be a hydrogel when in an oxidized state and can be a solution when in a reduced state. A solution of the copolymer can be oxidized to form a hydrogel

and the hydrogel can be reduced to form a solution of the copolymer. The solution can be dehydrated to produce the dry copolymer for storage. Furthermore, the present invention also relates to methods of making and using the reversible hydrogel systems.

Priority: US2002-425764P Applic. Date: 2002-11-13

Inventor: RAVI NATHAN [US]


Patent No.: US8192722B2  Issued: 05/Jun/2012

Title: ABUSE-PROOF DOSAGE FORM

Applicant/Assignee: GRUNENTHAL GMBH

Application No.: 12/140665   Filing Date: 17/Jun/2008

Abstract:

The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.

Priority: US2006-462216 Applic. Date: 2006-08-03; DE20031036400 Applic. Date: 2003-08-06; DE200510005446 Applic. Date: 2005-02-04; US2003-718112 Applic. Date: 2003-11-20; US2006-348295 Applic. Date: 2006-02-06; US2006-349544 Applic. Date: 2006-02-06

Inventor: ARKENAU-MARIC ELISABETH [DE]; BARTHOLOMAUS JOHANNES [DE]; KUGELMANN HEINRICH [DE]


Patent No.: US8192751B2  Issued: 05/Jun/2012

Title: COMPOSITION FOR PROMOTING BONE REGENERATION AND RESTORATION

Applicant/Assignee: HANS BIOMED.COR

Application No.: 12/523264   Filing Date: 17/Oct/2007

Abstract:

A bone grafting material composite is provided. The bone grafting material composite includes a demineralized bone matrix (DBM) and a carboxymethyl cellulose (CMC)/glycerol gel carrier. Due to the CMC/glycerol gel carrier, the implantation ability thereof is better than that of the DBM. Therefore, the bone grafting material composite can be easily used, so that a curative effect can be greatly improved. In addition, since the CMC/glycerol gel is used as a carrier, the composite with a mobility maintained is washed out by water after surgery, so that the composite can be fixed on a damaged portion of a bone.

Priority: KR20070004362 Applic. Date: 2007-01-15; WO2007KR05090 Applic. Date: 2007-10-17

Inventor: KIM JIN-YOUNG [KR]; AHN JAE-HYOUNG [KR]; SONG SEOK-BEAM [KR]; CHAE JI-HWA [KR]; SEO SEOG-JIN [KR]; KANG KE-WON [KR]; HWANG HO-CHAN [KR]; LEE JUNG-SUK [KR]


Patent No.: US8192756B2  Issued: 05/Jun/2012

Title: GASTRIC RETAINED GABAPENTIN DOSAGE FORM

Applicant/Assignee: DEPOMED, INC

Application No.: 13/111575   Filing Date: 19/May/2011

Abstract:

A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.

Priority: US2001-335248P Applic. Date: 2001-10-25; US2002-280309 Applic. Date: 2002-10-25; US2008-239591 Applic. Date: 2008-09-26; US2010-749101 Applic. Date: 2010-03-29

Inventor: BERNER BRET [US]; HOU SUI YUEN EDDIE [US]; GUSLER GLORIA M [US]


Patent No.: US8192759B2  Issued: 05/Jun/2012

Title: Matrix made of polyester polymers entangled with hyaluronic polymers useful for supporting tissue repair

Applicant/Assignee: ISTO TECHNOLOGIES, INC

Application No.: 11/179425   Filing Date: 11/Jul/2005

Abstract:

The present application discloses matrix compositions to support the repair of tissue defects such as an osteochondral injury. A matrix described herein comprises a polyester polymer entangled with a polysaccharide polymer. Also disclosed are methods of preparing a matrix, and methods of using a matrix in the repair of tissue. In certain configurations, a matrix can comprise a polyester cross-linked with a polysaccharide, which can be an oxidized polysaccharide. In some configurations, a matrix can further comprise one or more additional components, such as a growth factor.

Priority: US2004-587088P Applic. Date: 2004-07-12

Inventor: SEYEDIN MITCHELL S [US]; SPIRO ROBERT [US]


Patent No.: US8192760B2  Issued: 05/Jun/2012

Title: Methods and Compositions for Treating Tissue Using Silk Proteins

Applicant/Assignee: ABBOTT CARDIOVASCULAR SYSTEMS INC

Application No.: 11/566643   Filing Date: 04/Dec/2006

Abstract:

Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier.

In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.

Priority:

Inventor: HOSSAINY SYED [US]; NGO MICHAEL [US]; TROLLSAS MIKAEL [US]; STANKUS JOHN [US]; MICHAL GENE [US]


Patent No.: US8193251B2  Issued: 05/Jun/2012

Title: Method for producing products with water clusters

Applicant/Assignee: D&Y LABORATORIES, INC

Application No.: 12/592873   Filing Date: 03/Dec/2009

Abstract:

A method of producing products includes diluting a mater in a quality water as a dilution water a plurality of times until solid stable water clusters are formed having a plurality of water molecules connected with one another by electrical dipole interaction via internal electric field of ions and having a permanent electric dipole moment with an electrical field surrounding the solid stable water clusters, and the produced solid stable water clusters can be used with an additional material to produce the final product.

Priority: US2008-200821P Applic. Date: 2008-12-04; US2008-200823P Applic. Date: 2008-12-04; US2008-200824P Applic. Date: 2008-12-04; US2008-200825P Applic. Date: 2008-12-04; US2009-210064P Applic. Date: 2009-03-14; US2009-210065P Applic. Date: 2009-03-14; US2009-217604P Applic. Date: 2009-06-02; US2009-217605P Applic. Date: 2009-06-02; US2009-217680P Applic. Date: 2009-06-03

Inventor: LO SHUI YIN [US]; GANN DAVID [US]; XU GENG [US]


Patent No.: US8198087B2  Issued: 12/Jun/2012

Title: Tissue engineering support

Applicant/Assignee: SOFRADIM PRODUCTION SAS

Application No.: 11/881839   Filing Date: 30/Jul/2007

Abstract:

Cell cultures or tissue engineering supports, include at least a porous matrix based on a collagen sponge which defines first pores and a porous three-dimensional knit which defines second pores, the porous matrix filling the three-dimensional knit and all the first and second pores being at least partially interconnected with one another.

Priority:

Inventor: BAYON YVES [FR]; GRAVAGNA PHILIPPE [FR]; MENEGHIN ALFREDO [FR]; THERIN MICHEL [FR]; LEFRANC OLIVIER [FR]


Patent No.: US8198292B2  Issued: 12/Jun/2012

Title: Vinpocetine and eburnamonine derivatives for promoting bone growth, treating renal damage and cancer, and devices thereof

Applicant/Assignee: OSTEOGENEX INC, OSTEOGENEX, INC

Application No.: 12/494670   Filing Date: 30/Jun/2009

Abstract:

The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The compounds include the salts, hydrates and isomers thereof. The present invention also provides methods for the treatment of renal disease and cancer.

Priority: US2008-078163P Applic. Date: 2008-07-03

Inventor: ELLIES DEBRA [US]; ROSENBERG WILLIAM [US]


Patent No.: US8202548B2  Issued: 19/Jun/2012

Title: Chlorine dioxide gel and associated methods

Applicant/Assignee: DHARMA IP, LLC

Application No.: 11/879920   Filing Date: 19/Jul/2007

Abstract:

A method of making a composition having the property of being able to store chlorine dioxide includes mixing an aqueous chlorine dioxide solution with a superabsorbent, water-soluble polymer that is substantially unreactive with chlorine dioxide and permitting a mixture formed thereby to form one of a gel and a solid composition. A method of delivering chlorine dioxide includes providing a gel or solid composition as described and degelling the gel or dissolving the solid composition to dispense the chlorine dioxide therefrom. A method of disinfecting a target such as water, wastewater, or a surface comprises delivering chlorine dioxide as above and permitting the polymer to precipitate out of the mixture. Aqueous chlorine dioxide is then recovered and applied to the target.

Priority: US2003-682728 Applic. Date: 2003-10-09; US2007-803518 Applic. Date: 2007-05-15

Inventor: LEE SUNGGYU [US]; ROBERTS PATRICIA [US]


Patent No.: US8202833B2  Issued: 19/Jun/2012

Title: Composition containing biocompatible polymerization accelerator and polymerizable material

Applicant/Assignee: SURMODICS, INC

Application No.: 10/723505   Filing Date: 26/Nov/2003

Abstract:

The present invention provides method and materials for forming a polymeric matrix having improved biocompatible properties. A polymerization accelerator is provided that includes an N-vinyl group and a biocompatible functional group. The polymerization accelerator is particularly useful for the polymerization of macromers, which can be used to form biocompatible polymeric coatings on the surface of biological materials, such as cells and tissue.

Priority:

Inventor: SWAN DALE G [US]; CHUDZIK STEPHEN J [US]; OFSTEAD RONALD F [US]


Patent No.: US8206738B2  Issued: 26/Jun/2012

Title: Hydrogel compositions with an erodible backing member

Applicant/Assignee: CORIUM INTERNATIONAL, A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESIS, RUSSIAN ACADEMY OF SCIENCES, CORIUM INTERNATIONAL, INC, A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESIS

Application No.: 10/661103   Filing Date: 12/Sep/2003

Abstract:

A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.

Priority: US2003-359548 Applic. Date: 2003-02-05; US2002-137664 Applic. Date: 2002-05-01; US2001-288008P Applic. Date: 2001-05-01

Inventor: SINGH PARMINDER [US]; FAASSE ADRIAN [US]; CLEARY GARY W [US]; MUDUMBA SRI [US]; FELDSTEIN MIKHAIL M [RU]; BAIRAMOV DANIR R [RU]


Patent No.: US8206743B2  Issued: 26/Jun/2012

Title: PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

Applicant/Assignee: VASCULAR BIOGENICS LTD

Application No.: 13/018447   Filing Date: 01/Feb/2011

Abstract:

Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.

Priority: US2004-988487 Applic. Date: 2004-11-14; US2002-135447 Applic. Date: 2002-05-01; WO2001IL01059 Applic. Date: 2001-11-15; US2004-490746 Applic. Date: 2004-04-12; WO2002IL00339 Applic. Date: 2002-05-01; US2000-248582P Applic. Date: 2000-11-17; US2001-330118P Applic. Date: 2001-10-19

Inventor: HARATS DROR [IL]; GREENBERGER SHOSHANA [IL]; BREITBART EYAL [IL]; BANGIO LIVNAT [IL]; PELED MICHAEL [IL]


Patent No.: US8211471B2  Issued: 03/Jul/2012

Title: PROCESS FOR THE PRODUCTION OF BEADLETS

Applicant/Assignee: DSM IP ASSETS B.V

Application No.: 12/416638   Filing Date: 01/Apr/2009

Abstract:

A process for the production of cross-linked beadlets containing one or more active ingredients selected from the group of a fat-soluble vitamin active material, a carotenoid and a polyunsaturated fatty acid is provided. The process comprises treating a dry particulate form at a temperature in the range of from 90 DEG C. to 140 DEG C. for a time period of from 30 seconds to 30 minutes or from 1 minute to 10 minutes or from 3 minutes to 7 minutes.

Priority: EP20030007009 Applic. Date: 2003-03-27; US2005-542049 Applic. Date: 2005-07-13; WO2004EP02821 Applic. Date: 2004-03-18

Inventor: DIGUET SYLVAIN [FR]; HUBER TORSTEN [CH]; ULM JOHANN [CH]


Patent No.: US8221790B2  Issued: 17/Jul/2012

Title: THERAPEUTIC POLYESTERS AND POLYAMIDES

Applicant/Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Application No.: 11/956189   Filing Date: 13/Dec/2007

Abstract:

Polymers (i.e. polyesters, polyamides, and polythioesters or a mixture thereof) which degrade hydrolytically into biologically active compounds are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver biologically active compounds to a host are also provided.

Priority: US2000-220707P Applic. Date: 2000-07-27; US2004-753048 Applic. Date: 2004-01-06; US2001-917194 Applic. Date: 2001-07-27; US2001-261337P Applic. Date: 2001-01-12

Inventor: UHRICH KATHRYN E [US]


Patent No.: US8221791B1  Issued: 17/Jul/2012

Title: Silica-based antibacterial and antifungal nanoformulation

Applicant/Assignee: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC

Application No.: 12/332021   Filing Date: 10/Dec/2008

Abstract:

A silica-based nanoformulation and method is used to treat citrus canker, inhibit the growth of mold and mildew, and add nutrients to soil used for agricultural purposes. The nanotechnology-enabled copper-loaded, silica nanoformulation (CuSiNP/NG) design is a "revolutionary re-invention" of Cu for safe application because it provides a formulation with maximum abundance of ionic Cu, provides sustained and optimal Cu ion release for long-term disease protection, better adherence to plant surfaces and structural surfaces due to gel-based nanostructure of CuSiNG, thus avoiding multiple spray applications and reducing the amount of Cu used in comparison to existing Cu compounds without compromising antibacterial activity. Thus, the silica-based nanoformulation releases copper in non-toxic quantities to the environment and the silica matrix provides an environmentally safe host material with a flexible design that is optimized to provide specific antifungal and antibacterial remediation using infrequent applications.

Priority:

Inventor: SANTRA SWADESHMUKUL [US]


Patent No.: US8222233B2  Issued: 17/Jul/2012

Title: MODIFICATIONS OF SOLID 3-SN-PHOSPHOGLYCERIDES

Applicant/Assignee: BIOMOLECULAR PRODUCTS, INC

Application No.: 13/087738   Filing Date: 15/Apr/2011

Abstract:

Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.

Priority: US2001-328660P Applic. Date: 2001-10-11; WO2002US32647 Applic. Date: 2002-10-11; US2004-492252 Applic. Date: 2004-08-05; US2008-142370 Applic. Date: 2008-06-19

Inventor: YESAIR DAVID W [US]; SHAW WALTER A [US]; BURGESS STEPHEN W [US]; MCKEE ROBERT TRAVIS [US]


Patent No.: US8227401B2  Issued: 24/Jul/2012

Title: OPTICALLY ACTIVE MUSCONE COMPOSITION AND FRAGRANCES OR COSMETICS CONTAINING THE SAME

Applicant/Assignee: TAKASAGO INTERNATIONAL CORPORATION

Application No.: 13/219005   Filing Date: 26/Aug/2011

Abstract:

(Problem) The object of the invention relates to a development of a new musk-feeling fragrance material which is a highly scenting musk-feeling fragrance, and is to provide a fragrance composition which, when added to fragrances or cosmetics, can improve the fixative property and express a high performance and excellent musky aromatic quality. (Means for resolution) A fragrance composition is prepared using, as the active ingredient, a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 90:10 to 95:5 (weight ratio) in terms of weight ratio, or a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 75:25 to 80:20 (weight ratio) in terms of weight ratio.

Priority: US2010-853581 Applic. Date: 2010-08-10; US2007-719109 Applic. Date: 2007-05-11; WO2004JP16825 Applic. Date: 2004-11-12

Inventor: YAMAMOTO KENICHI [JP]; YAGI MISAO [JP]; MATSUDA HIROYUKI [JP]; MARUYAMA KENJI [JP]


Patent No.: US8231897B2  Issued: 31/Jul/2012

Title: HYDROSTATIC DELIVERY SYSTEM FOR CONTROLLED DELIVERY OF AGENT

Applicant/Assignee:

Application No.: 12/131807   Filing Date: 02/Jun/2008

Abstract:

The present invention provides a hydrostatic delivery system including a hydrostatic couple and an agent of interest. The hydrostatic couple includes at least one hydrodynamic fluid-imbibing polymer, and at least one hydrostatic pressure modulating agent. This delivery system has the ability to control the release of one or more agents of interest within a fluid environment following zero-order kinetics.

Priority: US2000-251751P Applic. Date: 2000-12-05; US2002-006740 Applic. Date: 2002-04-02

Inventor: MACGREGOR ALEXANDER [CA]


Patent No.: US8231898B2  Issued: 31/Jul/2012

Title: CONTROLLED RELEASE HYDROCODONE FORMULATIONS

Applicant/Assignee: PURDUE PHARMA LP, PURDUE PHARMA L.P

Application No.: 12/914054   Filing Date: 28/Oct/2010

Abstract:

A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

Priority: US2009-378586 Applic. Date: 2009-02-17; US2003-660349 Applic. Date: 2003-09-11; US2001-016651 Applic. Date: 2001-10-30; US2000-244424P Applic. Date: 2000-10-30

Inventor: OSHLACK BENJAMIN [US]; HUANG HUA-PIN [US]; MASSELINK JOHN K [US]; TONELLI ALFRED P [US]


Patent No.: US8231905B2  Issued: 31/Jul/2012

Title: GASTRIC RETAINED GABAPENTIN DOSAGE FORM

Applicant/Assignee: DEPOMED, INC

Application No.: 13/301644   Filing Date: 21/Nov/2011

Abstract:

A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.

Priority: US2001-335248P Applic. Date: 2001-10-25; US2002-280309 Applic. Date: 2002-10-25; US2008-239591 Applic. Date: 2008-09-26; US2010-749101 Applic. Date: 2010-03-29; US201113111575 Applic. Date: 2011-05-19

Inventor: BERNER BRET [US]; HOU SUI YUEN EDDIE [US]; GUSLER GLORIA M [US]


Patent No.: US8231906B2  Issued: 31/Jul/2012

Title: Transdermal estrogen device and delivery

Applicant/Assignee: NOVEN PHARMACEUTICALS, INC

Application No.: 12/216811   Filing Date: 10/Jul/2008

Abstract:

Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.

Priority:

Inventor: MANTELLE JUAN [US]


Patent No.: US8231929B2  Issued: 31/Jul/2012

Title: Medical Device Coating Process

Applicant/Assignee: COOK MEDICAL TECHNOLOGIES LLC

Application No.: 11/877369   Filing Date: 23/Oct/2007

Abstract:

Methods for coating medical devices for implantation within a body vessel are provided comprising providing a cylindrical container, placing a medical device inside the cylindrical container, and applying a polymer in liquid form inside the container.

Priority: US2006-857908P Applic. Date: 2006-11-09

Inventor: SUN JICHAO [US]


Patent No.: US8232264B2  Issued: 31/Jul/2012

Title: Compositions and methods for enhancing corticosteroid delivery

Applicant/Assignee: MEDICIS PHARMACEUTICAL CORPORATION

Application No.: 12/322346   Filing Date: 29/Jan/2009

Abstract:

The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.

Priority: US2001-037360 Applic. Date: 2001-12-21; US2004-825977 Applic. Date: 2004-04-16

Inventor: GANS EUGENE H [US]; WORTZMAN MITCHELL S [US]


Patent No.: US8232301B2  Issued: 31/Jul/2012

Title: PESTICIDAL COMPOSITIONS

Applicant/Assignee: DOW AGROSCIENCES LLC, DOW AGROSCIENCE, LLC

Application No.: 12/537276   Filing Date: 07/Aug/2009

Abstract:

A pesticidal composition comprising a pesticide, an ammonium salt, and a nonionic surfactant, is provided.

Priority: US2008-088020P Applic. Date: 2008-08-12

Inventor: BABCOCK JONATHAN M [US]; NOLTING STEVEN PAUL [US]


Patent No.: US8232304B2  Issued: 31/Jul/2012

Title: Antifungal formulations

Applicant/Assignee: G & R PHARMACEUTICALS, LLC

Application No.: 10/691928   Filing Date: 23/Oct/2003

Abstract:

A topical composition and the method using the composition, which contains an antifungal agent and a low potency anti-inflammatory steroid which is safe and effective such as desonide or its derivative. The low potency steroid agent does not cause side effects such as skin atrophy, striae and hypopigmentation. In a representative example, the low potency anti-inflammatory steroid has the following structure: wherein R1, R2, R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, and phenyl groups

R1 and R2 taken together can be C3-C10 cycloalkyl

and R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, phenyl, C7-C10 phenylalkyl, carboxylate, sulfonyl, phosphoryl, and phosphonyl groups.

The composition can be formulated in a dosage form such as a cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution. The composition can be used to treat a fungal disease such as tinea pedis, tinea capitis, tinea corporis, tinea versicolor, tinea cruris, and candidiasis as well as intertriginous dermatitis complicated by candidiasis.

Priority: US2002-421190P Applic. Date: 2002-10-24

Inventor: GOLDSTEIN JAY A [US]; ROTHMAN MICHAEL [US]; LO WHE-YONG [US]


Patent No.: US8236350B2  Issued: 07/Aug/2012

Title: POLYMER FOR TISSUE ENGINEERING APPLICATIONS AND DRUG DELIVERY

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Application No.: 12/533368   Filing Date: 31/Jul/2009

Abstract:

A biocompatible and biodegradable elastomeric polymer material, the polymer material comprising: glycerol and dodecanedioic acid, wherein the molar ratio of glycerol to dodecanedioic acid is from about 5:1 to about 1:5. Methods for using the biocompatible and biodegradable elastomeric polymer material comprises providing a PGD elastomeric polymer comprising glycerol and dodecanedioic acid, in a molar ratio of glycerol to dodecanedioic acid of about 1:1 and administering the PGD elastomeric polymer to a soft tissue defect site in need thereof.

Priority: US2008-137807P Applic. Date: 2008-08-01

Inventor: MIGNECO FRANCESCO [US]; HUANG YEN CHIH [US]; BIRLA RAVI K [US]; HOLLISTER SCOTT J [US]


Patent No.: US8236351B2  Issued: 07/Aug/2012

Title: TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Applicant/Assignee: PURDUE PHARMA L.P

Application No.: 12/909614   Filing Date: 21/Oct/2010

Abstract:

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.

Priority: US2003-689866 Applic. Date: 2003-10-21; US2001-781081 Applic. Date: 2001-02-08; US2000-181369P Applic. Date: 2000-02-08

Inventor: OSHLACK BENJAMIN [US]; WRIGHT CURTIS [US]; HADDOX J DAVID [US]


Patent No.: US8236848B2  Issued: 07/Aug/2012

Title: Diindolylmethane for the treatment of HPV infection

Applicant/Assignee: BIORESPONSE L.L.C.,, BIORESPONSE, L.L.C

Application No.: 12/070115   Filing Date: 14/Feb/2008

Abstract:

New methods and compositions are disclosed that comprise the phytochemical Diindolylmethane, alone or in combination with immune potentiating steroids. These methods and compositions are utilized to treat subjects suffering from common cutaneous warts (verrucae) and Human Papilloma Virus (HPV) related conditions of the oropharynx, larynx, genitalia, and uterine cervix.

Priority: US2002-117288 Applic. Date: 2002-04-05; US2001-337563P Applic. Date: 2001-10-23

Inventor: ZELIGS MICHAEL A [US]


Patent No.: US8236863B2  Issued: 07/Aug/2012

Title: Saline solutions for clinical or cosmetic use

Applicant/Assignee: PHARMA SOL INTERNATIONAL LIMITED

Application No.: 10/490811   Filing Date: 26/Sep/2002

Abstract:

A saline solution for a clinical or cosmetic use which consists essentially of a solution in water of sodium ions in major amount and potassium ions in minor amount, together with physiologically acceptable counter ions, being isotonic or optionally slightly hypertonic or hypotonic with respect to blood plasma or tears or an otherwise relevant biological fluid, and being substantially free of calcium ions, magnesium ions, phosphate ions, bicarbonate ions and also glucose, sucrose, food starch or other glucose-releasing saccharides, for use as a more cell-friendly alternative to normal saline.

Priority: GB20010023115 Applic. Date: 2001-09-26; WO2002GB04387 Applic. Date: 2002-09-26

Inventor: SCHMIDT RYSZARD JAN [GB]; BIGGS JAMES MARTIN [US]


Patent No.: US8241649B2  Issued: 14/Aug/2012

Title: DERMATOLOGICAL/COSMETIC GELS COMPRISING AT LEAST ONE RETINOID AND/OR RETINOID SALT AND BENZOYL PEROXIDE

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: 13/103613   Filing Date: 09/May/2011

Abstract:

Dermatological/cosmetic gel compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise (i) at least one retinoid, (ii) dispersed benzoyl peroxide and (iii) at least one pH-independent gelling agent, formulated into (iv) a physiologically acceptable medium therefor.

Priority: FR20010016747 Applic. Date: 2001-12-21; US2008-076859 Applic. Date: 2008-03-24; US2002-326389 Applic. Date: 2002-12-23; US2002-351382P Applic. Date: 2002-01-28

Inventor: ORSONI SANDRINE [FR]; WILLCOX NATHALIE [FR]


Patent No.: US8241650B2  Issued: 14/Aug/2012

Title: Device, method, and use for treatment of neuropathy involving nitric oxide

Applicant/Assignee: NOLABS AB

Application No.: 11/891678   Filing Date: 10/Aug/2007

Abstract:

A device is provided that allows for target treatment of neuropathy, such as diabetic peripheral neuropathy, or neuropathy and ulcers resulting from said neuropathy. The device comprises a nitric oxide (NO) eluting polymer arranged to contact a treatment area, such that a therapeutic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said area. The nitric oxide (NO) eluting polymer is integrated with a carrier material, such that the carrier material, in use, regulates and controls the elution of the therapeutic dosage of nitric oxide (NO). Furthermore, a corresponding manufacturing method for the device is disclosed.

Priority: EP20050002935 Applic. Date: 2005-02-11; EP20050018269 Applic. Date: 2005-08-23; WO2006EP50891 Applic. Date: 2006-02-13; US2005-652760P Applic. Date: 2005-02-14; US2005-711006P Applic. Date: 2005-08-24

Inventor: PETERS TOR [SE]


Patent No.: US8241660B2  Issued: 14/Aug/2012

Title: PATCH FOR THE EXPULSION OF INSECT POISON FROM THE SKIN AFTER STINGS FROM MEMBRANOUS INSECTS (HYMENOPTERA)

Applicant/Assignee:

Application No.: 12/377796   Filing Date: 20/Aug/2007

Abstract:

This invention relates to a patch for the expulsion of insect poison from the skin after stings from membranous insects (Hymenoptera). The patch is characterized in comprising a poison-aspirating matrix comprising an expulsion agent as well as a swell layer, which swells after the addition of a liquid through a hole on the top of the patch and thus adds a light pressure to the poison-aspirating matrix towards the skin, whereby a local and relieving effect is achieved. In one embodiment, the matrix further comprises a local anesthetic. The expulsion agent is e.g. a carbohydrate. The swell layer consists e.g. of a silica gel.

Priority: WO2007IB02386 Applic. Date: 2007-08-20; DK20060001095 Applic. Date: 2006-08-23; DK20070000706 Applic. Date: 2007-05-11

Inventor: WENCKENS MARTIN [DK]


Patent No.: US8241668B2  Issued: 14/Aug/2012

Title: THERAPEUTIC POLYESTERS AND POLYAMIDES

Applicant/Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Application No.: 11/956202   Filing Date: 13/Dec/2007

Abstract:

Polymers (i.e. polyesters, polyamides, and polythioesters or a mixture thereof) which degrade hydrolytically into biologically active compounds are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver biologically active compounds to a host are also provided.

Priority: US2001-261337P Applic. Date: 2001-01-12; US2000-220707P Applic. Date: 2000-07-27; US2001-917194 Applic. Date: 2001-07-27; US2004-753048 Applic. Date: 2004-01-06

Inventor: UHRICH KATHRYN E [US]


Patent No.: US8242076B2  Issued: 14/Aug/2012

Title: POLYPEPTIDES, MATRICES, HYDROGELS AND METHODS OF USING SAME FOR TISSUE REGENERATION AND REPAIR

Applicant/Assignee: RAMOT AT TEL AVIV UNIVERSITY LTD, THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER, RAMOT AT TEL-AVIV UNIVERSITY LTD

Application No.: 12/673520   Filing Date: 13/Aug/2008

Abstract:

A novel laminin polypeptide comprising the amino acid sequence set forth by SEQ ID NO:3 is disclosed. Also disclosed are compositions-of-matter comprising a polysaccharide (e.g., hyaluronic acid) and the novel laminin polypeptide

or hyaluronic acid, a laminin polypeptide and an antioxidant (e.g., superoxide dismutase), as well as matrices and hydrogels comprising same which can be used for ex vivo or in vivo tissue formation and for treatment of pathologies characterized by diseased, damaged or loss of tissue.

Priority: US2007-935487P Applic. Date: 2007-08-15; WO2008IL01120 Applic. Date: 2008-08-13

Inventor: ROCHKIND SHIMON [IL]; NEVO ZVI [IL]


Patent No.: USRE43582E1  Issued: 14/Aug/2012

Title: Semi-moist delivery system

Applicant/Assignee: EZ-MED HOLDINGS, INC

Application No.: 12/426396   Filing Date: 29/Apr/2009

Abstract:

The subject invention is a carrier or product formed of a matrix having starch, sugar, fat, polyhydric alcohol and water in suitable ratios such that there exists a water activity of 0.6-0.75. The water activity of the product matrix may be adjusted up or down so that the availability of water in the finished product is not detrimental to the included active ingredient, be it pharmaceutical, nutraceutical, or a vitamin mineral complex.

Priority: US1998-160618 Applic. Date: 1998-09-24; US2003-639909 Applic. Date: 2003-08-13

Inventor: CHRISTENSEN EDWIN H [US]


Patent No.: US8246980B2  Issued: 21/Aug/2012

Title: Transdermal delivery system

Applicant/Assignee: UCB PHARMA GMBH

Application No.: 10/627990   Filing Date: 28/Jul/2003

Abstract:

An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains an amine-functional drug in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of the amine-functional drug and is impermeable to the protonated form of the amine-functional drug.

Priority: EP20020016864 Applic. Date: 2002-07-30; US2003-451715P Applic. Date: 2003-03-05

Inventor: SCHACHT DIETRICH WILHELM [DE]; HANNAY MIKE [DE]; WOLFF HANS-MICHAEL [DE]


Patent No.: US8252302B2  Issued: 28/Aug/2012

Title: Methods and Compositions To Treat Hemorrhagic Conditions of The Brain

Applicant/Assignee: EDGE THERAPEUTICS, INC

Application No.: 13/032514   Filing Date: 22/Feb/2011

Abstract:

The described invention provides a nonhuman animal model system for hemorrhagic brain conditions, methods for evaluating a substance for treating the hemorrhagic brain condition in a mammal, methods for treating hematoma expansion or recurrent rebleeding resulting from hemorrhagic brain conditions in a mammal, and pharmaceutical compositions for administration into or at a distance proximal to the hemorrhagic brain condition.

Priority: US2007-943124P Applic. Date: 2007-06-11; US2008-137320 Applic. Date: 2008-06-11; US2010-306758P Applic. Date: 2010-02-22; US2007-976902P Applic. Date: 2007-10-29

Inventor: MACDONALD R LOCH [CA]


Patent No.: US8252322B2  Issued: 28/Aug/2012

Title: Delivery system with increased bioavailability

Applicant/Assignee: CORN PRODUCTS DEVELOPMENT, INC

Application No.: 10/453011   Filing Date: 03/Jun/2003

Abstract:

The present invention is directed to a dry composition which allows delivery of active agents with good bioavailability. These compositions are prepared by emulsifying the active agent using liposome technology known in the art and then encapsulating with a modified starch. The modified starch is prepared by enzymatic hydrolysis of starch after the preparation of a starch derivative containing a hydrophobic group or both a hydrophobic and a hydrophilic group. The resultant composition is a dry powder with excellent bioavailability. Further, the composition has good load levels and stability.

Priority:

Inventor: TRUBIANO PAOLO C [US]; KARRAS AFAF [US]


Patent No.: US8252332B2  Issued: 28/Aug/2012

Title: GASTRIC RETAINED GABAPENTIN DOSAGE FORM

Applicant/Assignee:

Application No.: 12/749101   Filing Date: 29/Mar/2010

Abstract:

A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.

Priority: US2001-335248P Applic. Date: 2001-10-25; US2002-280309 Applic. Date: 2002-10-25; US2008-239591 Applic. Date: 2008-09-26

Inventor: BERNER BRET [US]; HOU SUI YUEN EDDIE [US]; GUSLER GLORIA M [US]


Patent No.: US8252333B2  Issued: 28/Aug/2012

Title: Biodegradable, non-toxic biological adhesive for use in abdominal surgery

Applicant/Assignee:

Application No.: 11/507623   Filing Date: 22/Aug/2006

Abstract:

A biological adhesive formulation comprising dextrin, at least one adhesiveness modifier agent, and at least one antibiotic is suitable for promoting healing of tissue in a patient, for example, to prevent anastomosis of a surgical wound in the digestive system of a patient, and for affixing a prosthesis during a hernia operation.

Priority: US2006-762136P Applic. Date: 2006-01-26

Inventor: CUETO-GARCIA JORGE [MX]


Patent No.: US8257478B2  Issued: 04/Sep/2012

Title: Use of marine fungus originated compounds as antifouling agents

Applicant/Assignee: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY

Application No.: 11/303610   Filing Date: 16/Dec/2005

Abstract:

Compounds originally isolated from marine fungi are useful as antifouling (antibacterial and/or anti-larval settlement) agents. The compounds are 3-chloro-2,5-dihydroxy benzyl alcohol, cyclo-(Pro-Phe),3-methyl-N-(2-phenylethyl) butanamide, and succinic acid. The compounds are non-toxic or low-toxic. They can be used alone or in combination, as active ingredients for making environment-friendly antifouling formulations/coatings.

Priority: US2004-636092P Applic. Date: 2004-12-16

Inventor: QIAN PEI-YUAN [CN]; LI XIANCUI [CN]; KWONG FUK NING [CN]; YANG LAI HUNG [CN]; DOBRETSOV SERGEY VLADIMIROVICH [CN]


Patent No.: US8257737B2  Issued: 04/Sep/2012

Title: Tissue implants and methods for making and using same

Applicant/Assignee:

Application No.: 10/216552   Filing Date: 09/Aug/2002

Abstract:

The invention provides biocompatible, biodegradable calcium sulfate matrices containing calcium sulfate activated platelets for use in tissue formation. The matrices are particularly useful in stimulating hard tissue, for example, bone formation. The matrices may also further include a growth factor and/or a transfectable gene, the inclusion of which may be useful in stimulating the growth of tissue of interest.

Priority: US2001-311216P Applic. Date: 2001-08-09

Inventor: INTINI GIUSEPPE [US]; ANDREANA SEBASTIANO [US]; DZIAK ROSEMARY [US]; BOBEK LIBUSE ANNA [US]


Patent No.: US8257738B2  Issued: 04/Sep/2012

Title: ENCAPSULATION COMPOSITIONS AND PROCESS FOR PREPARING THE SAME

Applicant/Assignee: MCCORMICK & COMPANY, INC, MCCORMICK & COMPANY, INCORPORATED

Application No.: 12/844380   Filing Date: 27/Jul/2010

Abstract:

Encapsulation compositions in which an encapsulate (A) is encapsulated in a matrix (B) may be prepared by: (i) mixing matrix (B) with a liquid plasticizer and encapsulate (A) in an extruder, to obtain a melted mixture of encapsulate (A) and matrix (B)

and (ii) extruding the melted mixture, to obtain an extruded mixture.

Priority: US2004-864631 Applic. Date: 2004-06-10; US2002-096665 Applic. Date: 2002-03-14; US2001-275484P Applic. Date: 2001-03-14

Inventor: PORZIO MICHAEL A [US]; ZASYPKIN DMITRIY [US]


Patent No.: US8257741B2  Issued: 04/Sep/2012

Title: Solid pharmaceutical dispersions with enhanced bioavailability

Applicant/Assignee: PFIZER INC, BEND RESEARCH, INC

Application No.: 10/458840   Filing Date: 09/Jun/2003

Abstract:

Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.

Priority: US1998-131019 Applic. Date: 1998-08-07; US1997-055221P Applic. Date: 1997-08-11; US2001-770562 Applic. Date: 2001-01-26

Inventor: CURATOLO WILLIAM J [US]; HERBIG SCOTT M [US]; NIGHTINGALE JAMES A S [US]


Patent No.: US8258189B2  Issued: 04/Sep/2012

Title: Compounds prepared by adding an oxetane derivative to an alcohol

Applicant/Assignee: CECALC

Application No.: 12/682769   Filing Date: 30/Sep/2008

Abstract:

The invention relates to compositions obtained by the reaction of an alcohol having a variable nature and that can be modified beforehand by the addition of alkylene oxide, and of a substrate characterized by an oxetane pattern and at least one hydroxyl function.

Priority: FR20070058306 Applic. Date: 2007-10-15; WO2008FR51751 Applic. Date: 2008-09-30

Inventor: DA COSTA GEORGES [FR]; GUILBOT JEROME [FR]; MULLER DANIEL [FR]; ROLLAND HERVE [FR]


Patent No.: US8263102B2  Issued: 11/Sep/2012

Title: Drug delivery coating for use with a stent

Applicant/Assignee: ATRIUM MEDICAL CORPORATION

Application No.: 11/236908   Filing Date: 28/Sep/2005

Abstract:

A coated medical device an a method of providing a coating on an implantable medical device result in a medical device having a bio-absorbable coating. The coating includes a bio-absorbable carrier component. In addition to the bio-absorbable carrier component, a therapeutic agent component can also be provided. The coated medical device is implantable in a patient to effect controlled delivery of the coating, including the therapeutic agent, to the patient.

Priority: US2004-613745P Applic. Date: 2004-09-28

Inventor: LABRECQUE ROGER [US]; MOODIE GEOFFREY [US]; FERRARO JOSEPH [US]; ROGERS LISA [US]; MARTAKOS PAUL [US]; KARWOSKI THEODORE [US]; HERWECK STEVE A [US]


Patent No.: US8263127B2  Issued: 11/Sep/2012

Title: PHOTOCHEMICAL ACTIVATION OF SURFACES FOR ATTACHING BIOMATERIAL

Applicant/Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA

Application No.: 12/633593   Filing Date: 08/Dec/2009

Abstract:

A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon

a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell

a hydrophilic group

and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon.

The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell.

Priority: US2005-250877 Applic. Date: 2005-10-14; WO2004US11861 Applic. Date: 2004-04-16; US2004-545127P Applic. Date: 2004-02-17; US2005-691416P Applic. Date: 2005-06-17

Inventor: ALFERIEV IVAN [US]; FISHBEIN ILIA [US]; CHORNY MICHAEL [US]; LEVY ROBERT J [US]; YELLEN BENJAMIN [US]; WILLIAMS DARRYL [US]


Patent No.: US8263529B2  Issued: 11/Sep/2012

Title: Herbicide composition

Applicant/Assignee: KAO CORPORATION

Application No.: 11/658998   Filing Date: 27/Sep/2005

Abstract:

The invention relates to a herbicide composition containing (A) an amino acid-based herbicide and (B) a compound having a branched structure represented by formula (1): R1CH2O-(R2O)nH (1) wherein R1 represents a C3 to C29 branched alkyl or branched alkenyl group, R2 represents a C2 to C4 alkylene group, and n is a mean number in the range of 1 to 30.

Priority: JP20040278837 Applic. Date: 2004-09-27; JP20050275135 Applic. Date: 2005-09-22; WO2005JP18254 Applic. Date: 2005-09-27

Inventor: SUZUKI TADAYUKI [JP]; MANBA AKIO [JP]; PRASETYO HERRY [ID]; HERMAWANTO FERRY [ID]; SUHARYANTO [ID]; MULJATI SRI [ID]


Patent No.: US8263663B2  Issued: 11/Sep/2012

Title: AZIDE FUNCTIONALIZED PEPTIDE TARGETING GROUPS

Applicant/Assignee: INTEZYNE TECHNOLOGIES, INC

Application No.: 12/961918   Filing Date: 07/Dec/2010

Abstract:

The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.

Priority: US2009-644110 Applic. Date: 2009-12-22; US2006-396872 Applic. Date: 2006-04-03; US2005-667260P Applic. Date: 2005-04-01; US2005-741780P Applic. Date: 2005-12-01

Inventor: SILL KEVIN N [US]; SKAFF HABIB [US]; BREITENKAMP KURT [US]; BREITENKAMP REBECCA [US]


Patent No.: US8263664B2  Issued: 11/Sep/2012

Title: PH-SENSITIVE POLYMERIC MICELLES FOR DRUG DELIVERY

Applicant/Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Application No.: 12/487574   Filing Date: 18/Jun/2009

Abstract:

Mixed micelles containing poly(L-histidine-co-phenylalanine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers exhibiting multidrug resistance. Targeting ligands, such as folate, can also be attached to the mixed micelles for enhancing drug delivery into cells. Methods of treating a warm-blooded animal with such a drug are disclosed.

Priority: US2002-381970P Applic. Date: 2002-05-19; US2003-640739 Applic. Date: 2003-05-19; US2004-846487 Applic. Date: 2004-05-14

Inventor: KIM DONGIN [US]; GAO ZHONGGAO [US]; LEE EUN SEONG [US]; BAE YOU HAN [US]


Patent No.: US8268240B2  Issued: 18/Sep/2012

Title: Ciclesonide-containing sterile aqueous suspension

Applicant/Assignee: NYCOMED GMBH

Application No.: 12/461647   Filing Date: 19/Aug/2009

Abstract:

The present invention provides methods of manufacturing a sterile ciclesonide-containing aqueous suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension.

Priority: JP20020193399 Applic. Date: 2002-07-02; US2005-519484 Applic. Date: 2005-07-21; WO2003JP08410 Applic. Date: 2003-07-02

Inventor: NISHIBE YOSHIHISA [JP]; NAGANO ATSUHIRO [JP]; TAKANASHI KAZUYA [JP]; UEJIMA YASUHIDE [JP]


Patent No.: US8268333B2  Issued: 18/Sep/2012

Title: Orally administered agent and an orally administered agent/supporting substrate complex

Applicant/Assignee: LINTEC CORPORATION

Application No.: 12/591700   Filing Date: 30/Nov/2009

Abstract:

With an object of providing an orally administered agent (in particular a film-shaped orally administered agent) with which the ease and safety of taking the agent are improved, to attain this object, in an orally administered agent 1b having one drug-containing layer 11 and two water-swellable gel-forming layers 12, the water-swellable gel-forming layers 12 are provided, either directly or via intermediate layers, on the both faces of the drug-containing layer 11.

Priority: WO2002JP03920 Applic. Date: 2002-04-19; US2006-540952 Applic. Date: 2006-10-02; WO2005JP04569 Applic. Date: 2005-03-15; JP20010125804 Applic. Date: 2001-04-24; JP20040106854 Applic. Date: 2004-03-31; US2003-690811 Applic. Date: 2003-10-23

Inventor: NOGAMI EIJI [JP]


Patent No.: US8268341B2  Issued: 18/Sep/2012

Title: STABLE NON-AQUEOUS SINGLE PHASE VISCOUS VEHICLES AND FORMULATIONS UTILIZING SUCH VEHICLES

Applicant/Assignee: INTARCIA THERAPEUTICS, INC

Application No.: 13/454063   Filing Date: 23/Apr/2012

Abstract:

This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 110-7 reciprocal second.

Priority: US201113043288 Applic. Date: 2011-03-08; US2008-075435 Applic. Date: 2008-03-11; US2000-627531 Applic. Date: 2000-07-28; US2000-497422 Applic. Date: 2000-02-03; US1999-119170P Applic. Date: 1999-02-08

Inventor: BERRY STEPHEN A [US]; FEREIRA PAMELA J [US]; DEHNAD HOUDIN [US]; MUCHNIK ANNA [US]


Patent No.: US8268349B2  Issued: 18/Sep/2012

Title: Solid Pharmaceutical Dosage Form

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 13/449958   Filing Date: 18/Apr/2012

Abstract:

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 DEG C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Priority: US201113240119 Applic. Date: 2011-09-22; US2004-925442 Applic. Date: 2004-08-25; US2003-498412P Applic. Date: 2003-08-28

Inventor: ROSENBERG JOERG [DE]; REINHOLD ULRICH [DE]; LIEPOLD BERND [DE]; BERNDL GUNTHER [DE]; BREITENBACH JOERG [DE]; ALANI LAMAN [US]; GHOSH SOUMOJEET [US]


Patent No.: US8268351B2  Issued: 18/Sep/2012

Title: Matrix film tablet with controlled release of a natural mixture of conjugated estrogens

Applicant/Assignee: SOLVAY PHARMACEUTICALS GMBH, ABBOTT PRODUCTS GMBH

Application No.: 10/866094   Filing Date: 14/Jun/2004

Abstract:

A pharmaceutical matrix film tablet with controlled release of natural mixtures of conjugated estrogens which have been obtained from the urine of pregnant mares.

Priority: EP20010129830 Applic. Date: 2001-12-14; WO2002EP14103 Applic. Date: 2002-12-12

Inventor: THUMBECK BERND [DE]; BUDDE KLAUS [DE]; KRISTEN GERHARD [DE]; WIARDS MARGIT [DE]


Patent No.: US8273372B2  Issued: 25/Sep/2012

Title: EXTRACELLULAR MATRIX COMPOSITION

Applicant/Assignee: RESTORATION OF APPEARANCE & FUNCTION TRUST

Application No.: 12/304907   Filing Date: 15/Jun/2007

Abstract:

The invention relates to a process for preparing an extracellular matrix composition comprising cross-linked fibrinogen or a derivative thereof, to an extracellular matrix composition obtained by the process and to the use of the composition in wound healing, tissue regeneration or as a tissue engineering scaffold.

Priority: GB20060011986 Applic. Date: 2006-06-16; WO2007GB02238 Applic. Date: 2007-06-15; US2006-804996P Applic. Date: 2006-06-16; GB20070009099 Applic. Date: 2007-05-11

Inventor: DYE JULIAN [GB]


Patent No.: US8273373B2  Issued: 25/Sep/2012

Title: PHOTOCROSSLINKED BIODEGRADABLE HYDROGEL

Applicant/Assignee: CASE WESTERN RESERVE UNIVERSITY

Application No.: 12/649700   Filing Date: 30/Dec/2009

Abstract:

A photocrosslinked biodegradable hydrogel includes a plurality of natural polymer macromers cross-linked with a plurality of hydrolyzable acrylate cross-links. The hydrogel is cytocompatible and produces substantially non-toxic products upon degradation.

Priority: US2008-141266P Applic. Date: 2008-12-30

Inventor: ALSBERG EBEN [US]; JEON OJU [US]


Patent No.: US8277845B2  Issued: 02/Oct/2012

Title: FORMULATIONS AND METHODS FOR LYOPHILIZATION AND LYOPHILATES PROVIDED THEREBY

Applicant/Assignee: REMEDY PHARMACEUTICALS, INC

Application No.: 12/746164   Filing Date: 03/Dec/2008

Abstract:

The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer

b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest

and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.

Priority: US2007-992241P Applic. Date: 2007-12-04; WO2008US85384 Applic. Date: 2008-12-03

Inventor: JACOBSON SVEN [US]


Patent No.: US8282967B2  Issued: 09/Oct/2012

Title: NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS

Applicant/Assignee: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Application No.: 13/168597   Filing Date: 24/Jun/2011

Abstract:

The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.

Priority: US201113157036 Applic. Date: 2011-06-09; US2009-887041 Applic. Date: 2009-01-15; WO2006US20781 Applic. Date: 2006-05-30; US2005-685578P Applic. Date: 2005-05-27

Inventor: SCHOENFISCH MARK H [US]; SHIN JAE HO [US]; STASKO NATHAN [US]


Patent No.: US8287888B2  Issued: 16/Oct/2012

Title: THERMOSENSITIVE POLYPHOSPHAZENE-BIOACTIVE MOLECULE CONJUGATES, PREPARATION METHOD THEREOF AND USE THEREOF

Applicant/Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Application No.: 11/568852   Filing Date: 03/Nov/2006

Abstract:

The present invention relates to a poly(organophosphazene)-bioactive molecule conjugates in which biodegradable and thermosensitive poly(organophosphazene) with a functional group showing the sol-gel phase transition with change of temperature is combined with various bioactive molecules, such as drugs, a preparation method thereof, and a use thereof for delivery of bioactive molecules.

Priority: KR20060030731 Applic. Date: 2006-04-04; WO2006KR04574 Applic. Date: 2006-11-03; KR20060107229 Applic. Date: 2006-11-01

Inventor: SONG SOO-CHANG [KR]; LEE SUN-MI [KR]; KIM CHANG-WON [KR]


Patent No.: US8288347B2  Issued: 16/Oct/2012

Title: Dermal Fillers Comprising Silk Fibroin Hydrogels and Uses Thereof

Applicant/Assignee: ALLERGAN, INC

Application No.: 12/906777   Filing Date: 18/Oct/2010

Abstract:

The present specification provides compositions useful as dermal fillers and methods using such compositions to treat a condition of skin.

Priority: US2010-883139 Applic. Date: 2010-09-15; US2010-764039 Applic. Date: 2010-04-20; US2009-170895P Applic. Date: 2009-04-20

Inventor: COLLETTE ADAM L [US]; HORAN REBECCA L [US]; CHEN JINGSONG [US]; ALTMAN GREGORY H [US]


Patent No.: US8298517B2  Issued: 30/Oct/2012

Title: Personal Care Compositions Having Improved Compatibility and Providing Improved Sun Protection

Applicant/Assignee: DOW CORNING CORPORATION

Application No.: 12/993867   Filing Date: 06/Jul/2009

Abstract:

Personal care composition having improved compatibility and providing improved sun protection are obtained by including a liquid silicone resin having greater than 50 mole percent Me3SiO1/2 and PrSiC3/2 units, where Me is methyl and Pr is propyl in the composition. If desired to enable additional compatibility of ingredients comprising the personal care composition, the liquid silicone resin can also contain PhSiO3/2 or Ph2SiO2/2 units, where Ph is phenyl, or a mixture thereof.

Priority: US2008-084635P Applic. Date: 2008-07-30; WO2009US49662 Applic. Date: 2009-07-06; US2008-083189P Applic. Date: 2008-07-24

Inventor: HORSTMAN JOHN BERNARD [US]; KING DOUGLAS W [US]; PRETZER PAUL W [US]; SCHMIDT RANDALL [US]; WIEBER GARY [US]; LEAYM TINA [US]; PRETZER MARIA R [US]


Patent No.: US8303967B2  Issued: 06/Nov/2012

Title: BIOACTIVE BONE GRAFT SUBSTITUTE

Applicant/Assignee: ORTHOVITA, INC

Application No.: 11/771857   Filing Date: 29/Jun/2007

Abstract:

The invention relates to biocompatible bone graft materials for repairing bone defects and the application of such bone grafts. The devices of the invention comprise resorbable calcium phosphate, resorbable collagen, and bioactive glasses.

Priority: US2006-817617P Applic. Date: 2006-06-29

Inventor: CLINEFF THEODORE D [US]; KOBLISH ANTONY [US]; BAGGA CHARANPREET S [US]; ERBE ERIK M [US]; NAGVAJARA GINA M [US]; DARMOC MARISSA M [US]


Patent No.: US8303989B2  Issued: 06/Nov/2012

Title: COMPOSITIONS AND METHODS FOR INCREASING THE ORAL ABSORPTION OF ANTIMICROBIALS

Applicant/Assignee: INTERNATIONAL HEALTH MANAGEMENT ASSOCIATES, INC

Application No.: 12/425099   Filing Date: 16/Apr/2009

Abstract:

The present invention provides compositions and methods for increasing absorption of antibacterial agents, particularly third generation cephalosporin antibacterial agents, in oral dosage solid and/or suspension forms. Specifically, the composition is comprised of a biopolymer that is preferably swellable and/or mucoadhesive, a antimicrobial agent, and a cationic binding agent contained within the biopolymer such that the binding agent is ionically bound or complexed to at least one member selected from the group consisting of the biopolymer and the antimicrobial agent.

Priority: US2001-888114 Applic. Date: 2001-06-22; US2001-829405 Applic. Date: 2001-04-09; US2000-598089 Applic. Date: 2000-06-21; WO2001US19625 Applic. Date: 2001-06-18; US2001-283976P Applic. Date: 2001-04-16

Inventor: CHOI SEUNG-HO [US]; LEE JEOUNG-SOO [US]; KEITH DENNIS [US]


Patent No.: US8309065B2  Issued: 13/Nov/2012

Title: Hydrocarbon Mixture and Use Thereof

Applicant/Assignee: COGNIS IP MANAGEMENT GMBH

Application No.: 12/665425   Filing Date: 12/Jun/2008

Abstract:

The invention relates to hydrocarbon mixtures containing linear C11 and linear C13 hydrocarbons, wherein the sum of the linear C11 and linear C13 hydrocarbons is greater than or equal to 60 wt. % with relation to the sum of the hydrocarbons, and to the use of said mixtures in cosmetic and/or pharmaceutical preparations.

Priority: EP20070011967 Applic. Date: 2007-06-19; EP20070075513 Applic. Date: 2007-06-20; DE200810012458 Applic. Date: 2008-03-04; WO2008EP04699 Applic. Date: 2008-06-12

Inventor: ANSMANN ACHIM [DE]; DIERKER MARKUS [DE]; KAWA ROLF [DE]; BAEK YEAH-YOUNG [DE]; JACKWERTH BETTINA [DE]


Patent No.: US8309125B2  Issued: 13/Nov/2012

Title: Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Applicant/Assignee: WATSON PHARMACEUTICALS, INC

Application No.: 12/835945   Filing Date: 14/Jul/2010

Abstract:

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.

Priority: US2003-664803 Applic. Date: 2003-09-19; US2002-412180P Applic. Date: 2002-09-20; US2002-412181P Applic. Date: 2002-09-20

Inventor: KOSITPRAPA UNCHALEE [US]; NANGIA AVINASH [US]; CARDINAL JOHN [US]; GOLDFARB ROBERT I [US]


Patent No.: US8309129B2  Issued: 13/Nov/2012

Title: Nanoparticles comprising a drug, ethylcellulose, and a bile salt

Applicant/Assignee: BEND RESEARCH, INC

Application No.: 12/451287   Filing Date: 21/Apr/2008

Abstract:

A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, ethylcellulose, and a bile salt.

Priority: US2007-915696P Applic. Date: 2007-05-03; WO2008IB01059 Applic. Date: 2008-04-21

Inventor: MILLER WARREN KENYON [US]; MORGEN MICHAEL MARK [US]; SMITHEY DANIEL TOD [US]


Patent No.: US8309130B2  Issued: 13/Nov/2012

Title: ADSORBENT FOR ORAL ADMINISTRATION

Applicant/Assignee: KUREHA CHEMICAL INDUSTRIES CO., LTD, KUREHA CORPORATION

Application No.: 12/630581   Filing Date: 03/Dec/2009

Abstract:

An adsorbent for oral administration, characterized by comprising a spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m2/g or more, and a diffraction intensity ratio, an R value, determined by an equation (1): R=(I15-I35)/(I24-I35) (1) wherein I15 is a diffraction intensity when a diffraction angle (2[theta]) of an X-ray diffractometry is 15 DEG , I35 is a diffraction intensity when a diffraction angle (2[theta]) of an X-ray diffractometry is 35 DEG , and I24 is a diffraction intensity when a diffraction angle (2[theta]) of an X-ray diffractometry is 24 DEG , is 1.4 or more

and an adsorbent for an oral administration, characterized by comprising a surface-modified spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m2/g or more, a total amount of acidic groups is 0.40 to 1.00 meq/g, a total amount of basic groups is 0.40 to 1.10 meq/g, and a diffraction intensity ratio, an R value, determined by equation (1) is 1.4 or more.

The adsorbents for oral administration exhibit a useful selective adsorbability, that is, a less adsorbability of useful substances in a body, and a greater adsorbability of toxic substances.

Priority: JP20020320254 Applic. Date: 2002-11-01; US2004-948314 Applic. Date: 2004-09-24; WO2003JP14011 Applic. Date: 2003-10-31

Inventor: SONOBE NAOHIRO [JP]; MORIMOTO SUSUMU [JP]; YOSHIHARA HIDEYUKI [JP]; HANATSUKA HIROYUKI [JP]; ARAKAWA MAKOTO [JP]


Patent No.: US8309131B2  Issued: 13/Nov/2012

Title: ABSORBABLE PUTTY-LIKE IMPLANTS AND METHODS FOR THEIR USE FOR MECHANICAL HEMOSTASIS OF BONE AND FOR THE TREATMENT OF OSSEOUS DEFECTS

Applicant/Assignee: ORTHOCON, INC

Application No.: 13/173719   Filing Date: 30/Jun/2011

Abstract:

The present invention relates to mechanically hemostatic body-absorbable compositions having a putty-like consistency comprising a finely powdered, carboxylic acid salt, a liquid block copolymer of ethylene oxide and propylene oxide, and a tocopherol.

Priority: US2004-941889 Applic. Date: 2004-09-16; US2003-504979P Applic. Date: 2003-09-23

Inventor: KRONENTHAL RICHARD L [US]


Patent No.: US8309154B2  Issued: 13/Nov/2012

Title: Aerated food product with surface-active inorganic fibers

Applicant/Assignee: CONOPCO, INC

Application No.: 12/086095   Filing Date: 22/Nov/2006

Abstract:

There is provided a surface-active material that comprises fibers which have been modified so as to impart surface-active properties onto said fibres and giving it a contact angle between 60 DEG and 120 DEG , wherein the fibres have an aspect ratio of more than 10 to 1,000. The surface-active material can be used for foam and emulsion formation and stabilization, coatings, encapsulation and drug delivery. It can for example be used in the following industries: foods, home and personal care, oilfield, agriculture, textile, construction, emulsion polymerization, leather, plastic, pulp, paper and pharma.

Priority: EP20050077906 Applic. Date: 2005-12-16; WO2006EP11382 Applic. Date: 2006-11-22

Inventor: CAI YA [CN]; CAO JIAN [CN]; GOLDING MATTHEW DUNCAN [AU]; LIU WEICHANG [CN]; PAUNOV VESSELIN NIKOLAEV [GB]; PELAN EDWARD GEORGE [NL]; STOYANOV SIMEON DOBREV [NL]; ZHOU WEIZHENG [CN]


Patent No.: US8309613B2  Issued: 13/Nov/2012

Title: Solid Pharmaceutical Dosage Form

Applicant/Assignee: ABBOTT LABORATORIES, ABBVIE INC

Application No.: 12/880781   Filing Date: 13/Sep/2010

Abstract:

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 DEG C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Priority: US2004-925442 Applic. Date: 2004-08-25; US2003-498412P Applic. Date: 2003-08-28

Inventor: ROSENBERG JOERG [DE]; REINHOLD ULRICH [DE]; LIEPOLD BERND [DE]; BERNDL GUNTHER [DE]; BREITENBACH JOERG [DE]; ALANI LAMAN [US]; GHOSH SOUMOJEET [US]


Patent No.: US8309614B2  Issued: 13/Nov/2012

Title: POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY

Applicant/Assignee: CEDARS-SINAI MEDICAL CENTER

Application No.: 12/935110   Filing Date: 10/Apr/2009

Abstract:

The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.

Priority: US2008-044191P Applic. Date: 2008-04-11; WO2009US40252 Applic. Date: 2009-04-10

Inventor: DING HUI [US]; LJUBIMOVA JULIA Y [US]; HOLLER EGGEHARD [US]; BLACK KEITH L [US]


Patent No.: US8314154B2  Issued: 20/Nov/2012

Title: Topical skin care formulations

Applicant/Assignee:

Application No.: 12/284398   Filing Date: 22/Sep/2008

Abstract:

A topical anti-aging skin care formulation comprising an effective amount of a benzoquinone, such as CoQ10, plus a synergistic pair of stabilizers and a synergistic pair of whiteners. The stabilizers are octyl salicylate and octyl methoxycinnamate. The whiteners are titanium dioxide and zinc oxide. When proper amounts of these ingredients are used in an aqueous based emulsion formulation, the product will be initially white, and will remain white for an extended period of time.

Priority:

Inventor: HOLYFIELD LOUISE [US]


Patent No.: US8318204B2  Issued: 27/Nov/2012

Title: Ph Sensitive Block Copolymer and Polymeric Micelle Using the Same

Applicant/Assignee: SUNGKYUNKWAN UNIVERSITY FOUNDATIN FOR CORPORATE COLLOBORATION, SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION

Application No.: 11/573858   Filing Date: 27/Dec/2005

Abstract:

Disclosed is a pH-sensitive block copolymer obtained by copolymerization of: (a) a polyethylene glycol compound (A)

and (b) at least one poly(amino acid) compound selected from the group consisting of a poly([beta]-amino ester) and poly(amido amine) or a copolymer thereof (B). A method for preparing the same block copolymer, and a polymer micelle type drug composition comprising the pH-sensitive block copolymer and a physiologically active substance that can be encapsulated with the block copolymer are also disclosed. The pH-sensitive block copolymer is obtained by polymerization of a hydrophilic polyethylene glycol compound with a pH-sensitive biodegradable poly(amino acid) compound.

Therefore, the pH-sensitive block copolymer can form a micelle structure due to its amphiphilicity and ionization characteristics depending on pH variations, and thus can be used as drug carrier for target-directed drug delivery depending on pH variations in the body.

Priority: KR20050022726 Applic. Date: 2005-03-18; KR20050098219 Applic. Date: 2005-10-18; WO2005KR04566 Applic. Date: 2005-12-27

Inventor: LEE DOO SUNG [KR]; KIM MIN SANG [KR]


Patent No.: US8318797B2  Issued: 27/Nov/2012

Title: Composition and Methods for the Protection of Hair From Treated Pool Water

Applicant/Assignee:

Application No.: 12/608233   Filing Date: 29/Oct/2009

Abstract:

Compositions for treating hair are disclosed. Methods of making and using compositions for treating hair are also disclosed.

Priority: US2008-109869P Applic. Date: 2008-10-30

Inventor: PRESTY S KATHARINE [US]


Patent No.: US8318817B2  Issued: 27/Nov/2012

Title: CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS

Applicant/Assignee: OTONOMY, INC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 12/506127   Filing Date: 20/Jul/2009

Abstract:

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Priority: US2009-427663 Applic. Date: 2009-04-21; US2009-466310 Applic. Date: 2009-05-14; US2008-082450P Applic. Date: 2008-07-21; US2008-083871P Applic. Date: 2008-07-25; US2008-094384P Applic. Date: 2008-09-04; US2008-101112P Applic. Date: 2008-09-29; US2008-140033P Applic. Date: 2008-12-22

Inventor: LICHTER JAY [US]; LEBEL CARL [US]; PIU FABRICE [US]; YE QIANG [US]; DELLAMARY LUIS A [US]; TRAMMEL ANDREW M [US]; HARRIS JEFFREY P [US]


Patent No.: US8318818B2  Issued: 27/Nov/2012

Title: Topical composition, topical composition precursor, and methods for manufacturing and using

Applicant/Assignee: SKINVISIBLE PHARMACEUTICALS, INC

Application No.: 11/079158   Filing Date: 14/Mar/2005

Abstract:

A tropical composition is provided. The topical composition can be prepared by diluting a topical composition precursor with water and adding additional components, if desired. The topical composition precursor can be prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups wherein the alkylene groups contain at least 10 carbon atoms, and a hydrophilic polymer composition including repeating carboxylic groups and/or repeating hydroxyl groups. A topical composition precursor and methods for manufacturing and using a topical composition are provided by the invention.

Priority: US2002-154723 Applic. Date: 2002-05-23; US2001-933275 Applic. Date: 2001-08-20

Inventor: ROSZELL JAMES A [US]; JEZIOR BRUCE [US]


Patent No.: US8323693B2  Issued: 04/Dec/2012

Title: External preparation for wounds

Applicant/Assignee: MEDRX CO., LTD, NIPPON SHINYAKU CO., LTD

Application No.: 10/507522   Filing Date: 14/Sep/2004

Abstract:

There is provided an external preparation for wounds which has novel usability in treating skin damages accompanied by a large amount of exudation such as bedsores, skin ulcers, and burns, and yet has such advantages as observed in conventional medicines having been employed in treating these wounds. The external preparation for wounds comprises a water-soluble polymer and a crosslinking agent, and has powdery/granular or ointment form. After absorbing an exudation, the preparation undergoes phase transition from a sol to a gel by the action of ingredient of the preparation, and thus exhibits actions of adsorbing and eliminating necrotic tissues, and protecting the wounded parts. Subsequently, it can continuously absorb the exudation. After being used, it can be easily separated substantially as a mass, thereby exhibiting high therapeutic effects and usability.

Priority: JP20020069901 Applic. Date: 2002-03-14; JP20020120084 Applic. Date: 2002-04-23; JP20020189912 Applic. Date: 2002-06-28; WO2003JP02887 Applic. Date: 2003-03-12

Inventor: HAMAMOTO HIDETOSHI [JP]; YAMASAKI KEIKO [JP]; YOKOYAMA HIDEAKIRA [JP]; HIRATA AKIHIKO [JP]; FUJII TAKERU [JP]


Patent No.: US8329207B2  Issued: 11/Dec/2012

Title: COMPOSITIONS AND METHODS FOR THE SUSTAINED RELEASE OF BETA-ALANINE

Applicant/Assignee: NATURAL ALTERNATIVES INTERNATIONAL , INC. CORPORATION, NATURAL ALTERNATIVES INTERNATIONAL, INC

Application No.: 12/064005   Filing Date: 23/May/2006

Abstract:

Methods and compositions are provided for increasing the anaerobic working capacity of muscle and other tissues. Also provided are compositions formulated for the sustained release of free beta-alanine. Also provided is a dietary supplement formulated, for example, as a solid food product, an edible suspension, liquid or semi-liquid as described herein.

Priority: US2005-683985P Applic. Date: 2005-05-23; WO2006US20104 Applic. Date: 2006-05-23

Inventor: HARRIS ROGER [GB]; WISE JOHN [US]


Patent No.: US8329211B2  Issued: 11/Dec/2012

Title: Reinforced Absorbable Multi-Layered Fabric for Hemostatic Applications

Applicant/Assignee: ETHICON, INC

Application No.: 12/781235   Filing Date: 17/May/2010

Abstract:

The present invention is directed to a synthetic fabric comprising a multi-layered nonwoven fabric made from staples of a polyglycolide/polylactide copolymer, each layer having a different density. The multi-layer fabric can be used as a reinforced absorbable hemostat medical device.

Priority:

Inventor: MOLOYE-OLABISI OLAJOMPO [US]; SHETTY DHANURAJ S [US]; VAN HOLTEN ROBERT W [US]; ZHONG DEGANG [US]


Patent No.: US8329212B2  Issued: 11/Dec/2012

Title: Abuse Potential Reduction in Abusable Substance Dosage Form

Applicant/Assignee: TRAVANTI PHARMA INC, TEIKOKU PHARMA USA, INC

Application No.: 12/621619   Filing Date: 19/Nov/2009

Abstract:

The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

Priority: US2004-763628 Applic. Date: 2004-01-23

Inventor: ANDERSON CARTER R [US]; MORRIS RUSSELL L [US]


Patent No.: US8329219B2  Issued: 11/Dec/2012

Title: Methods For Producing ECM-Based Biomaterials

Applicant/Assignee: COOK BIOTECH INCORPORATED, COOK MEDICAL TECHNOLOGIES LLC

Application No.: 12/644607   Filing Date: 22/Dec/2009

Abstract:

A method for forming an extracellular matrix material (ECM) material includes providing at least an ECM composition containing ECM particles varying in their capacity for migration through a fluid medium, including at least one population of expanded ECM particles. The ECM composition is combined in a fluid medium to form a flowable ECM composition. The flowable ECM composition is subjected to a centrifugal force in a mold for a period of time sufficient to distribute the ECM particles according to differences in their physical characteristics. The ECM composition is dried to form a dried ECM material having a density gradient extending from a less dense region to a more dense region. The dried ECM material may formed as a porous, substantially acellular ECM material expandable in an aqueous fluid environment by at least 100% in volume.

Priority:

Inventor: FARRELL LAURA-LEE [US]; JOHNSON CHAD E [US]


Patent No.: US8329220B2  Issued: 11/Dec/2012

Title: CONTROLLED RELEASE FORMULATIONS

Applicant/Assignee: AEGIS THERAPEUTICS, LLC, THE UAB RESEARCH FOUNDATION

Application No.: 12/197179   Filing Date: 22/Aug/2008

Abstract:

The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.

Priority: US2007-957960P Applic. Date: 2007-08-24; US2008-086743P Applic. Date: 2008-08-06; US2008-188441P Applic. Date: 2008-08-07

Inventor: MAGGIO EDWARD T [US]; MEEZAN ELIAS [US]; PILLION DENNIS J [US]; MORGAN SARAH L [US]; BAGGOTT JOE [US]


Patent No.: US8329224B2  Issued: 11/Dec/2012

Title: ION EXCHANGE RESIN TREATED TO CONTROL SWELLING

Applicant/Assignee: COATING PLACE, INC

Application No.: 12/965191   Filing Date: 10/Dec/2010

Abstract:

The present invention provides a method and composition for loading one or more drugs in a solution onto one or more ion exchange resin particles to form a drug-loaded resin particle. The drug-loaded resin particle is separated from the solution and dried before recombining the drug-loaded resin particle with the solution to load more drugs onto the drug-loaded resin particle from the solution.

Priority: US2007-674921 Applic. Date: 2007-02-14; US2005-225834 Applic. Date: 2005-09-13

Inventor: HALL HARLAN [US]; MADSEN J SCOTT [US]


Patent No.: US8329870B2  Issued: 11/Dec/2012

Title: WATER SOLUBLE REACTIVE DERIVATIVES OF CARBOXY POLYSACCHARIDES AND FIBRINOGEN CONJUGATES THEREOF

Applicant/Assignee: HEPACORE LTD

Application No.: 12/522092   Filing Date: 06/Jan/2008

Abstract:

The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived from it. Methods of preparation and methods of use in tissue repair and regeneration are also disclosed.

Priority: US2007-878391P Applic. Date: 2007-01-04; WO2008IL00033 Applic. Date: 2008-01-06

Inventor: AMIT BOAZ [IL]; BARKAY-OLAMI HILLA [IL]; YAYON AVNER [IL]


Patent No.: US8333990B2  Issued: 18/Dec/2012

Title: Solid Pharmaceutical Dosage Form

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/880766   Filing Date: 13/Sep/2010

Abstract:

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 DEG C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Priority: US2004-925442 Applic. Date: 2004-08-25; US2003-498412P Applic. Date: 2003-08-28

Inventor: ROSENBERG JOERG [DE]; REINHOLD ULRICH [DE]; LIEPOLD BERND [DE]; BERNDL GUNTHER [DE]; BREITENBACH JOERG [DE]; ALANI LAMAN [US]; GHOSH SOUMOJEET [US]


Patent No.: US8333991B2  Issued: 18/Dec/2012

Title: GASTRIC RETAINED GABAPENTIN DOSAGE FORM

Applicant/Assignee: DEPOMED, INC

Application No.: 13/553622   Filing Date: 19/Jul/2012

Abstract:

A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.

Priority: US201113301644 Applic. Date: 2011-11-21; US201113111575 Applic. Date: 2011-05-19; US2010-749101 Applic. Date: 2010-03-29; US2008-239591 Applic. Date: 2008-09-26; US2002-280309 Applic. Date: 2002-10-25; US2001-335248P Applic. Date: 2001-10-25

Inventor: BERNER BRET [US]; HOU SUI YUEN EDDIE [US]; GUSLER GLORIA M [US]


Patent No.: US8333992B2  Issued: 18/Dec/2012

Title: Gastric Retained Gabapentin Dosage Form

Applicant/Assignee: DEPOMED, INC

Application No.: 13/560938   Filing Date: 27/Jul/2012

Abstract:

A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.

Priority: US2010-749101 Applic. Date: 2010-03-29; US2008-239591 Applic. Date: 2008-09-26; US2002-280309 Applic. Date: 2002-10-25; US2001-335248P Applic. Date: 2001-10-25

Inventor: BERNER BRET [US]; HOU SUI YUEN EDDIE [US]; GUSLER GLORIA M [US]


Patent No.: US8334323B2  Issued: 18/Dec/2012

Title: ALKYLENE OXIDE-CAPPED SECONDARY ALCOHOL ALKOXYLATES USEFUL AS SURFACTANTS

Applicant/Assignee: DOW GLOBAL TECHNOLOGIES LLC

Application No.: 12/808936   Filing Date: 23/Dec/2008

Abstract:

Disclosed are compositions of the formula wherein R1 and R2 are each independently hydrogen or a linear or branched alkyl group containing from (1) to about (18) carbon atoms, provided that R1 and R2 together contain from about (8) to about (18) carbon atoms, and further provided that less than about 10 mole percent of R1 or R2 is hydrogen

R3 is hydrogen or an alkyl radical containing from (1) to about (6) carbon atoms

R4 and R5 are each independently hydrogen or an alkyl radical containing from (2) to about (6) carbon atoms, provided that R4 and R5 together contain from (2) to about (6) carbon atoms

m is an average value ranging from (0) to about (10), and n is an average value ranging from about (3) to (about 40), provided that the group containing m and the group containing n may be exchanged with one another as to position

and z is an average value ranging from about (0.5) to about (5). These compositions are conveniently prepared by a process including at least two steps and are useful as surfactants.

Priority: US2008-020416P Applic. Date: 2008-01-11; WO2008US88188 Applic. Date: 2008-12-23

Inventor: VARINEAU PIERRE T [US]; YU WANGLIN [US]; WEBER KARA S [US]; RAND CYNTHIA L [US]


Patent No.: US8337893B2  Issued: 25/Dec/2012

Title: Sol-gel derived bioactive glass polymer composite

Applicant/Assignee: FLORIDA RESEARCH FOUNDATION, INC, UNIVERSITY OF

Application No.: 10/616884   Filing Date: 10/Jul/2003

Abstract:

A bioactive sol-gel solution includes a biocompatible polymer, a gelable inorganic base material, and at least one calcium and phosphorous molecular species. The base material can be an alkoxide, such as TEOS. The polymer acts as a viscosity modifier to the sol or gel, increases the viscosity range over which fibers can be sprayed or spun, and broadens the time period over which fibers can be sprayed or spun. A bioactive glass composite can be formed from the bioactive sol-gel solution, including a fibrous form. Fibers can serve as a scaffold for cell growth and in the repair of hard or soft tissue defects.

Priority: US2002-395186P Applic. Date: 2002-07-10

Inventor: HATCHER BRIAN M [US]; BRENNAN ANTHONY [US]; CUEVAS BRIAN [US]; SEEGERT CHARLES [US]


Patent No.: US8338151B2  Issued: 25/Dec/2012

Title: METHOD FOR CREATING INTRACELLULAR ARTIFICIAL NANOSTRUCTURES IN SITU

Applicant/Assignee: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY

Application No.: 12/194554   Filing Date: 20/Aug/2008

Abstract:

A method of creating intracellular artificial nanostructures in situ, which employees a chemical precursor. The precursor does not self-assemble due to the presence of a cleavable motif linked to it. When the precursor comes inside live cells by an uptaking mechanism on the cell membrane, the cleavable motif is then to be removed by an enzymatic action of a first enzyme. Without the cleavable motif, the precursor now engages in a self-assembling process to form nanostructures within the live cells, which may cause formation of a hydrogel. Furthermore, the self-assembling process can be made reversible by employing a second enzyme which puts the cleavable motif back to the precursor, whereby dissolving the nanostructures into solution.

Priority: US2008-063079 Applic. Date: 2008-02-06; WO2006US08333 Applic. Date: 2006-03-06; US2005-706072P Applic. Date: 2005-08-08

Inventor: XU BING [US]; YANG ZHIMOU [US]; XU KEMING [CN]